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Breast cancer is the most common cancer diagnosed in women, accounting for more than 1 
in 10 new cancer diagnoses each year.1 It is the second most common cause of death from 
cancer among women in the world.2 Breast cancer incidence has been increasing worldwide for 
decades.1 It is potentially one of the most curable of cancers with 5-year relative survival rates 
ranging from 60% to 92% in Europe and the United States.1,3 In line with these statistics, there is 
a steadily growing population of breast cancer survivors.4 Survivors of breast cancer represent 
a unique group of patients with specific complex health issues who often face the challenge of 
having to deal with multiple long-term side effects of treatment protocols.5 To facilitate a better 
transition from a patient with cancer to a survivor of cancer6 more attention from the medical 
community to try and prevent side effects from breast cancer treatment is warranted. 
Persistent pain after breast cancer surgery 
Chronic pain after surgery, referred to as persistent postsurgical pain (PPSP), is a condition 
leading to significant disease burden and reduced quality of life in affected individuals.7 PPSP is 
typically recognized as pain that: 1) lasts more than 3 months after surgery; 2) was not present 
before surgery or has different characteristics or increased intensity from preoperative pain; 3) 
is localized to the surgical site or a referred area; and 4) cannot be attributed to other causes.8-10 
The condition is common, with incidence estimates ranging from 10% to 50% of all postsurgical 
patients.8,11 The clinical problem of PPSP has been largely unrecognized historically, but 
prevention of PPSP is now considered one of the most important research priorities in surgery, 
anesthesia and perioperative medicine.12 
PPSP can occur after any type of surgical procedure, but breast cancer surgery may be among 
the procedures with particularly high risk for PPSP.8,11 A better understanding of the prevalence of 
PPSP after breast cancer surgery would be helpful to gauge the size of this problem for patients. 
It would also help prioritize PPSP after breast cancer surgery specifically as a condition requiring 
the development of preventative strategies. 
Demographic and clinical risk factors of PPSP after breast cancer surgery
Previously reported patient-related risk factors for PPSP after breast cancer surgery are age,13 
potassium channel genetic polymorphisms,14 and psychological factors such as anxiety and 
depression.15 Among treatment related risk factors more extensive surgery in the axilla, radiation 
therapy, and chemotherapy have been suggested as important risk factors.13,16  Recently, obesity 
and low-grade inflammation have also been suggested as potential risk factors for persistent 
pain.16,17 Verifying and identifying additional clinical and demographic risk factors for PPSP after 
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breast cancer surgery may provide important information for subsequent research on prediction 
and prevention of PPSP.
Pathophysiology of PPSP 
Basic and clinical pain research over the last decades has furthered the understanding of the 
transition from acute postoperative pain to PPSP by identifying molecular and cellular changes 
that occur in the peripheral and central nervous system after surgery. It is well acknowledged 
that pain after surgery is a specific entity that is neither an isolated inflammatory response 
nor an isolated nerve injury, but usually a combination of both.18 After surgery, inflammation 
and nerve injury lead to synaptic plasticity that amplifies pain signaling, a process referred 
to as pain sensitization. These neuroplastic changes have been shown to occur peripherally, 
in the spinal cord, as well as in the brain.19,20 The pain intensity that is perceived by a breast 
cancer surgical patient is therefore related to both the size of the nociceptive input from tissue 
damage as well as the extent of enhancement of input through sensitization. Postoperative 
pain sensitization not only leads to increased acute postoperative pain, but has also been 
linked to the subsequent development of PPSP21-23 as the initial nociceptive insult of surgery 
may sensitize pain processing in susceptible individuals for very long periods after surgery.19 
Because postoperative pain sensitization is considered an important factor in the development 
of PPSP, preventing postoperative pain sensitization may constitute an attractive mechanism-
based approach to prevent PPSP.19 Such therapies should focus on blocking the process of pain 
sensitization from nerve injury and inflammation.24-27
Nerve injury is common in the context of breast cancer surgery28 and axillary lymph node 
dissection is known to be associated with an increased incidence of PPSP after breast cancer 
surgery.29 Regional anesthetic blockade of nerve damage related nociceptive input through 
paravertebral block is known to be effective in reducing acute postoperative pain30,31 and may 
reduce the incidence of PPSP after breast cancer surgery.32 
Breast cancer surgery is also associated with an inflammatory response.33,34 The inflammatory 
component of pain after surgery is associated with the production of prostanoids.35 This 
production involves induction of cyclooxygenase-2 (COX-2) both peripherally and in the central 
nervous system.36 Peripherally, the production of prostanoids sensitizes peripheral nociceptors. 
In the central nervous system, sensitization and the accompanying sickness syndrome 
(fever, lethargy, diffuse pain, anorexia, etcetera) are induced by interleukin-1 beta causing the 
upregulation of COX-2 resulting in elevated prostaglandin E2 levels in the cerebrospinal fluid. This 
central response to inflammation can be inhibited by preventing central prostanoid production 
via blockade of interleukin-converting enzyme or COX-2, but not COX-1.36,37 Furthermore, a 
synergistic action between central and peripheral COX-2 inhibition has been suggested and 




The relative contributions of inflammation and nerve damage in causing pain and pain sensitization 
after breast cancer surgery are currently not known. To identify potential preventative treatments 
for acute pain and PPSP accompanying breast cancer surgery it is useful to better understand 
the relative contributions of inflammation and nerve damage. A prospective trial selectively 
inhibiting input from inflammation or neuronal damage may provide important information on the 
relative importance of either pathway and may identify treatments to prevent PPSP after breast 
cancer surgery. 
Quantitative sensory testing
Because pain sensitization after surgery is thought to play an important role in PPSP development, 
it is important to be able to quantify it. Pain sensitization is difficult to quantify using standard 
clinical examination procedures, but quantitative sensory testing (QST) may help to quantify the 
degree and extent of neuroplastic changes.38 QST refers to recording of the sensation caused 
by different standardized stimuli to obtain measures of sensory processing. Testing is typically 
performed on skin, mucosa, bone, or muscle tissue, and stimuli can include heat and cold, 
pressure, pinprick, vibration, or electrical current.39,40 To test endogenous analgesia (conditioned 
pain modulation), pain perception can be measured before and after the application of a 
conditioning stimulus like ice-water stimulation.41 Another presumed measurement of central pain 
processing is the temporal summation of pain (‘wind-up’ phenomenon42), which is measured by 
determining the perception of pain to a brief series of repetitive stimuli.43 To assess the role of 
pain sensitivity changes in the pathophysiology of PPSP after breast cancer surgery, there is a 
need to incorporate QST in clinical trials studying PPSP after breast cancer surgery. 
Current standardized QST protocols, such as the German Research Network on Neuropathic 
Pain protocol44 are quite extensive and may not be suitable to perform in breast cancer surgery 
patients. There is a need for a new standardized QST protocol that can provide repetitive 
measures of pain processing in patients undergoing breast cancer surgery over longer follow-
up periods. 
QST prediction of PPSP
In addition to the tracking of pain sensitization changes after surgery, QST has been suggested 
to be useful in preoperative prediction of an individual patient’s risk of eventually developing 
PPSP.45 The same breast cancer surgical procedure leads to PPSP in some patients whereas 
others remain pain free after the initial acute postoperative period. A better understanding of 
which patients are at risk of developing PPSP would help identify the subset of patients who 




In other types of surgery it has been shown that patients who preoperatively perceive more 
pain on QST (hyperalgesia), or who have impaired endogenous analgesia, experience more 
acute postoperative pain.46,47 Higher acute postoperative pain has been demonstrated to be 
an important risk factor for PPSP after different surgical procedures including gynecological 
surgery,48 inguinal herniorrhapy,49 and total hip arthroplasty.50  
If preoperative QST measures have a strong association with PPSP outcome after breast 
cancer surgery, this would facilitate targeted studies on perioperative and postoperative pain 
management strategies to assess if PPSP can be prevented in individuals at high risk.
There is a need for a systematic evaluation of the value of preoperative QST in predicting PPSP 
after breast cancer surgery and other types of surgery. 
Prediction models 
PPSP after breast cancer surgery is a complex medical problem and an increasingly diverse set 
of risk factors for PPSP are being identified. Combining large combinations of various predictors 
to provide meaningful and accurate prediction on an individual patient level is challenging using 
conventional statistical methods. Outside of the pain research specific literature, classification 
and prediction methods have evolved substantially over the last decades.51 There is a need to 
develop new prediction strategies using advances in data science to facilitate more accurate 
prediction of PPSP after breast cancer surgery. Applying such methods may also accelerate 





Persistent pain after breast cancer surgery is a complex medical entity for which more 
mechanism-based prediction and prevention strategies are needed. Therefore, the following 
research questions will be addressed in this thesis:
 •    What is the prevalence of PPSP after breast cancer surgery?
 •    What are demographic and clinical risk factors for PPSP after breast cancer surgery?
 •    Are preoperative QST measures related to PPSP after breast cancer surgery and other 
types of surgery?
 •    How can QST be used in research on PPSP after breast cancer surgery?
 •    Can perioperative COX-2 inhibition reduce early postoperative pain and sensitization after 
breast cancer surgery?
 •    Can perioperative COX-2 inhibition reduce the incidence of PPSP after breast cancer 
surgery?
 •    What future directions in research may be helpful in improving identification and prevention 




Chapter 2 presents an investigation into the prevalence and risk factors of PPSP after breast 
cancer surgery.
Chapter 3 provides a systematic review on the association between preoperative QST and 
PPSP.
Chapter 4 delineates how QST can be used in the context of research on PPSP after breast 
cancer surgery.
Chapter 5 describes the results of a randomized clinical trial on the effect of perioperative COX-
2 inhibition on postoperative sensory thresholds and PPSP.
Chapter 6 presents a narrative review on hypothesized future directions for research on PPSP 
after breast cancer surgery.
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Background: Identification of risk factors associated with persistent pain after breast cancer 
treatment is needed to develop prevention and treatment strategies to improve the quality of life 
for patients with breast cancer. 
Objectives: To identify factors associated with persistent pain in women undergoing breast 
cancer treatments. 
Study design: Retrospective study. 
Setting: Regional hospital in the Netherlands.
Methods: The primary outcome was pain associated with surgery at more than 6 months 
postoperatively and patients were stratified based on the associated visual analogue scale score 
they reported: reporting no pain as ‘no pain’, pain 1-29 mm as ‘mild pain’ and pain 30-100 mm 
as ‘moderate/severe pain’. Secondary outcomes were function, symptom, and total quality of life 
scores. Predefined risk factors analyzed for association with outcomes included: age, smoking 
status, diabetes, BMI, disease stage, surgery type, axillary lymph node dissection, reoperation, 
chemotherapy, radiotherapy, and hormone therapy.
Results: Of the 718 patients who were approached, 492 were included (follow-up 2.5±1.8 
years). 35 percent of patients developed persistent pain (N=122 ‘mild pain’, N=53 ‘moderate/
severe pain’). Age, BMI, surgery type, axillary lymph node dissection, disease stage, reoperation, 
chemotherapy and radiotherapy were identified as potential risk factors in univariable ordinal 
regression analyses (P<0.10). Age (P<0.01) and BMI (P=0.04) remained independently 
predictive in the multivariable model. BMI and age were associated with ORs of 1.04 (95%-
CI:1.00-1.08) and 0.97 (95%-CI:0.95-0.99), respectively per point and year increase. BMI was 
associated with a higher symptom score (r=0.14, P<0.01), a lower level of function (r=-0.11, 
P=0.01) and lower total quality of life scores (r=-0.13, P<0.01) .  
Limitations: The retrospective nature of this study makes it prone to response and 
misclassification bias. 
Conclusion: BMI and age may be risk factors for persistent postoperative pain after breast 
cancer treatment. 
Key words: persistent postsurgical pain; breast cancer treatment; BMI; age; chronic 
postoperative pain; breast cancer surgery.




Persistent pain after treatment of breast cancer is a significant clinical problem due to its effect 
on quality of life and its general resistance to treatment.1,2 The incidence of persistent pain after 
treatment of breast cancer has been well documented in the past and has been reported to 
be around 20-30%.3,4 Recent advancements in the protocols for breast cancer management, 
including chemotherapy protocols, radiation therapy cycles, and surgical approaches to lymph 
node dissection, lumpectomy, and mastectomy seem to have lowered the incidence and severity 
of persistent pain after breast cancer treatment.5-9 However, moderate to severe persistent pain 
still affects ~15% of women.10   
There are likely multiple pathogenic mechanisms underlying persistent pain after breast 
cancer treatment. Among patient-related risk factors are age,11 genetic polymorphisms,12 
and psychological factors such as anxiety and depression.13 Among treatment-related risk 
factors more extensive surgery in the axilla, radiation therapy, and chemotherapy have all been 
suggested as important risk factors.11,14 Recently, obesity and low-grade inflammation have also 
been identified as potential risk factors for persistent pain.14,15
More data on the multiple demographic and treatment factors likely associated with persistent 
pain after breast cancer treatment are needed to develop prevention and treatment strategies 
in order to improve the quality of life for patients with breast cancer. In this large retrospective 
cohort study, we examined the prevalence and factors associated with persistent pain after 
breast cancer surgery and adjuvant treatments. 
METHODS
Study population
We identified patients who were treated for unilateral non-metastasized breast cancer from a 
registry of surgical procedures. All patients were treated at a regional hospital in the Netherlands 
(Reiner de Graaf Gasthuis, Delft) between September 2005 and September 2008. Inclusion 
criteria were: age 18 years or older and surgery either by lumpectomy or mastectomy for 
suspected breast carcinoma. Patients with a preoperatively known pain disorder were excluded. 
This study was conducted according to the guidelines of the Central Committee on Research 
Involving Human Subjects in the Netherlands (approval nr. 09 - 057) and the principles outlined 




The clinical outcome was persistent pain at long-term follow up.  Patients were asked to fill 
out a questionnaire at least 6 months postoperatively and were asked “do you have persistent 
pain due to your surgery?”. Additionally, they rated their current pain intensity on a 100 mm 
visual analogue scale (VAS). Patients were stratified into three categories: patients reporting no 
pain related to surgery were classified as ‘no pain’, patients reporting  pain related to surgery 
were classified into categories based on their reported VAS score: 1-29 mm was considered 
‘mild pain’ and 30-100 mm was considered ‘moderate/severe pain’. These cut-off scores are 
regularly applied in pain research and recent studies on persistent pain after breast cancer 
surgery followed a similar approach.10,14,17 
Secondary outcomes
Secondary outcomes included various quality of life scores obtained from the European 
Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC-30).18 
We calculated function, symptom and total quality of life scores as previously described.19 
Additionally, patients were asked if they had developed lymphedema as a result of treatment. 
Risk factors associated with outcomes 
We investigated demographic and treatment factors that have previously been reported 
to potentially influence persistent pain after treatment for breast cancer.11 Our predefined 
risk factors were: age, smoking status (smoking vs. no smoking), diabetes (diabetes vs. no 
diabetes), BMI, histopathological disease stage, surgery type (mastectomy vs. lumpectomy), 
axillary lymph node dissection (axillary lymph node dissection vs. no axillary lymph node 
dissection), reoperation (reoperation vs. no reoperation), chemotherapy (chemotherapy vs. no 
chemotherapy), radiotherapy (radiotherapy vs. no radiotherapy) and hormone therapy (hormone 
therapy vs. no hormone therapy).
Data retrieval 
Patient characteristics, medical history, performed intervention and pathology reports were 
collected retrospectively from medical records. Height and weight for BMI calculation were 
extracted from the preoperative visit. 
Data analysis
Demographics and clinical data for patients within our predefined subgroups of ‘no pain’, ‘mild 
pain’ and ‘moderate/severe pain’ are presented as mean ± standard deviation, or as median 
and interquartile range (IQR) when not normally distributed. Association of risk factors with 
study outcomes followed a two-step procedure: First, all risk factors (see above) were analyzed 
using univariate ordinal logistic regression. Results from these analyses are presented as odds 
ratios (ORs) with 95% confidence intervals (CI) as well as the corresponding P-value. Second, 
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risk factors associated with study outcome in univariate models (P<0.10) were included in 
a multivariable ordinal logistic regression model. Additional analyses were performed on the 
risk factors that remained independently predictive in the multivariate analysis to assess the 
distribution of the other risk factors among them. Logistic probability plots were generated for 
the independent significant predictors to aid in the interpretation of the results. These plots are 
helpful to determine the risk associated with a specific clinical value of a risk factor, because 
they display the related risk (and confidence interval) throughout the range of possible values 
for the factor. 
Function, symptom and total quality of life scores showed non-normally distributed residuals, 
therefore the Wilcoxon rank-sum test and Spearman’s correlation were used to perform 
univariate analysis of association between risk factors and secondary outcomes. The software 
package JMP, version 12 (SAS Institute Inc, Cary, NC, USA) was used for the statistical analyses. 
A statistical expert was consulted with regard to the analyses. 
A subsequent study, in the patient population that developed mild or moderate/severe pain, is 
currently under revision at another journal that focuses on pain medicine. That study investigated 
whether a neuropathic component of persistent postsurgical pain can be reliably detected using 
questionnaires. 
RESULTS
Seven hundred and eighteen eligible women were sent questionnaires and asked to participate. 
Four hundred and ninety-two patients completed the questionnaires (~69% response rate). 
Table 1 shows the characteristics of participating patients as well as the characteristics of all the 
screened patients (no significant differences). The mean duration of follow-up was 927 ± 682 
days (median 850 ± IQR 789).
Primary clinical outcome
Out of four hundred ninety-two, three hundred seventeen patients (64%) reported no persistent 
pain associated with surgery and they were classified as having ‘no pain’. One hundred twenty-
two (25%) patients developed mild persistent pain and fifty-three (11%) developed moderate/
severe persistent pain. The average clinical pain scores in the ‘mild’ and ‘moderate/severe’ 
groups were 14 ± 8 and 45 ± 13 mm VAS, respectively, at long term follow up (>6 months). 
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Table 1. Patient characteristics. 
Studied Patients 
(N=492)
All screened patients 
(N=718)
Age in years, mean ± SD 61 ± 12 63 ± 13
Smoking, n (%) 68 (14)
Diabetes, n (%) 47 (9)
BMI in kg/m2, mean ± SD 26 ± 5 
Mastectomy (instead of lumpectomy), n (%) 230 (46) 337 (47)
Axillary lymph node dissection, n (%) 186 (37) 263 (37)
Reoperation, n (%) 195 (39) 272 (38)
Chemotherapy, n (%) 229 (46) 300 (42)
Radiotherapy, n (%) 323 (65) 466 (65)
Hormone therapy, n (%) 264 (53) 371 (52)
Disease stage, n (%)
0 44 (9) 61 (9)
IA 171 ( 36) 245 (35)
IB 16 (3) 20 (3)
IIA 118 (25) 188 (26)
IIB 71 (15) 92 (13)
IIIA 41 (9) 56 (8)
IIIB 10 (2) 19 (3)
IIIC 9 (2) 20 (3)
Student’s T-test and chi-squared testing were employed to compare studied patients to all screened patients, 
characteristics were comparable between groups (P>0.05). BMI = Body Mass Index.
Risk factors for primary outcome 
Preliminary univariable analyses identified eight risk factors potentially associated with 
development of persistent postoperative pain. These were age (P<0.01), BMI (P=0.06), surgery 
type (P=0.07) axillary lymph node dissection (P<0.01), reoperation (P=0.01), chemotherapy 
(P<0.01), radiotherapy (P=0.03), and histopathological disease stage (P=0.02) - Table 2. None 
of the other predefined risk factors were associated with development of persistent post-operative 
pain (all P>0.10). Chemotherapy treatments consisted of adriamycin and cyclofosfamide 
(n=106), adriamycin and cyclofosfamide followed by a taxane (n=52), a taxane, adriamycin and 
cyclofosfamide together (n=45) or another regimen (n=18). The type of chemotherapy was not 
associated with persistent pain (chi-squared test, P>0.05). 
Multivariable analysis showed that age (P<0.01) and BMI (P=0.04) were independently and 
significantly associated with the development of persistent pain. The corresponding ORs and 
95% CI for all risk factors in the multivariable model are reported in Table 3. 




























































































































































































































































































































































































































































































































































































































































































































Table 3. Multivariable analysis of risk factors associated with persistent postoperative pain. 
Risk factor Multivariate analysis
OR (95% CI) P-value
Age 0.97 (0.95 – 0.99) <0.01
BMI  1.04 (1.00 – 1.08) 0.04
Stage 1.07 (0.90 – 1.23) 0.45
Axillary lymph node dissection 1.22 (0.74 – 2.01) 0.44
Reoperation  1.30 (0.86 – 1.96) 0.22
Chemotherapy 1.23 (0.71 – 2.14) 0.46
Surgery type 0.72 (0.41 – 1.25) 0.25
Radiotherapy 1.22 (0.68 – 2.19) 0.50
The odds ratios (ORs) are based on changes of 1 year for age, 1 kg/m2 for body mass index (BMI), and 1 
for stage. Multivariate analysis included parameters potentially associated with development of persistent 
post-operative pain in univariate analysis.
We also assessed the distribution of other risk factors throughout the range of BMI and age 
values (Table 4 - 7). BMI was stratified into groups <25 kg/m2 (normal), 25-30 kg/m2 (overweight) 
and >30 kg/m2 (obese).20 Age was categorized as ≤50 or >50.14 We found that overweight and 
obese patients had more diabetes than patients with a normal BMI (P<0.01) and that overweight 
patients were slightly older than patients with a normal BMI (P=0.03) (Table 4). When we compared 
younger (≤50) patients to older (>50) patients we found that younger patients presented with 
higher grade tumors, as evidenced by higher rates of IIB and IIIA tumors (Table 7). Consistently, 
younger women underwent more extensive treatments with higher rates of mastectomy (P<0.01), 
axillary lymph node dissection (P=0.01), reoperation (P=0.02), chemotherapy (P<0.01), hormone 
therapy (P<0.01) and a lower rate of radiotherapy (P<0.01) (Table 6).     
PERSISTENT PAIN AFTER BREAST CANCER TREATMENT
29
2
Table 4. Risk factors among different BMI strata.  
Risk factor BMI <25 
(n=252)
BMI 25 - 30  
(n=155)
BMI >30  
(n=76)
P-value
BMI (kg/m2), mean±SD 22.6 ± 1.7 27.2 ± 1.3 34.3 ± 3.9 N/A
Smoking, n (%) 33 (13) 25 (16) 6 (8) 0.21
Diabetes, n (%) 7 (3) 17 (11)a 18 (24)a,b <0.01
Age (years), mean±SD 60.0 ± 12.5 62.8 ± 11.3a 61.5 ± 11.4 0.03
Mastectomy, n (%) 119 (47) 66 (43) 33 (43) 0.68
Axillary lymph node dissection, n (%) 101 (40) 48 (32) 30 (40) 0.20
Reoperation, n (%) 105 (42) 58 (38) 27 (36) 0.54
Chemotherapy, n (%) 115 (46) 67 (44) 39 (53) 0.44
Radiotherapy, n (%) 155 (62) 107 (70) 49 (65) 0.21
Hormone therapy, n (%) 130 (52) 85 (56) 39 (52) 0.73
Comparison by Pearson Chi Squared tests and One-Way ANOVA with Tukey’s HSD. aDifferent vs. <25.0, 
bDifferent vs. BMI 25-30. BMI = Body Mass Index
Table 5. Histopathological disease stage among different BMI strata.  
Risk factor BMI 18.5 - 25 
(n=248)
BMI 25 - 30 
(n=151)




0 26 (10) 13 (9) 3 (4) N/A
IA 86 (35) 63 (42) 25 (34) N/A
IB 11 (4) 3 (2) 2 (3) N/A
IIA 57 (23) 40 (26) 20 (27) N/A
IIB  41 (17)  15 (10)  13 (18) N/A
IIIA 22 (9) 9 (6) 7 (10) N/A
IIIB 2 (1) 3 (2) 2 (3) N/A
IIIC  2 (1) 4 (3) 1 (1) N/A
IV 1 (0) 1 (1) 0 (0) N/A
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Table 6. Risk factors between younger and older patients.  
Risk factor Age ≤50  
(n=100)
Age >50  
(n=392)
P-value
Age (years), mean±SD 45.2 ± 4.8 65.1 ± 9.7 N/A
Smoking, n (%) 12 (12) 56 (14) 0.58
Diabetes, n (%) 5 (5.0) 41 (10.4) 0.09
BMI (kg/m2), mean±SD 25.6 ± 5.2 26.0 ± 4.5 0.42
Mastectomy, n (%) 59 (59) 170 (43) <0.01
Axillary lymph node dissection, n (%) 48 (48) 138 (35) 0.01
Reoperation, n (%) 50 (50) 145 (37) 0.02
Chemotherapy, n (%) 82 (81) 147 (37) <0.01
Radiotherapy, n (%) 54 (53) 269 (68) <0.01
Hormone therapy, n (%) 66 (65) 197 (50) <0.01
Comparison by unpaired T-test or Pearson’s Chi-Squared test. 
Comparison by Pearson’s Chi-Squared test. BMI = Body Mass Index
Table 7. Histopathological disease stage between different age groups.  
Risk factor Age ≤50  
(n=98)




0 4 (4) 40 (10) 0.09
IA 27 (28) 146 (38) 0.08
IB  1 (1) 16 (4) 0.24
IIA 27 (28) 93 (24) 0.54
IIB 22 (22) 51 (13) 0.03
IIIA 14 (14) 27 (7) 0.03
IIIB 0 (0) 7 (2) 0.39
IIIC 1 (1) 8 (2) 0.79
IV 2 (2) 1 (0) 0.20
Comparison by Pearson’s Chi-Squared test.
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The probability plots for persistent postoperative pain based on age and BMI within the different 
BMI and age strata are shown in Figures 1 & 2 
Figure 1. Probability of being in the different ordinal persistent postoperative pain categories at >6 months 
postoperatively based on Body Mass Index (BMI) ± 95%-confidence interval. The relationship between BMI 
and probabilities of being in the different ordinal pain categories is shown for different age strata. 
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Figure 2. Probability of being in the different ordinal persistent postoperative pain categories at >6 months 
postoperatively based on age ± 95% confidence interval. The relationship between age and probabilities of 
being in the different ordinal pain categories is shown for different Body Mass Index (BMI) strata. 
Secondary clinical outcomes 
As in the primary analysis, a higher BMI was associated with a higher symptom score (r=0.14, 
P<0.01) lower functioning score (r=-0.11, P=0.01), and lower total score (r=-0.13, P<0.01 - 
Table 8). Other risk factors associated with poorer quality of life scores were: diabetes, axillary 
lymph node dissection, histopathological disease stage and chemotherapy. None of the other 
predefined risk factors were associated with quality of life scores (all P>0.10). Because of 
the non-normal distribution of the quality of life residual scores we were unable to assess the 
identified risk factors in a multivariable model. 
One-hundred and eleven patients (22%) reported to suffer from lymphedema. Seventy-six (68%) of 
these patients underwent axillary lymph node dissection. Significantly higher rates of lymphedema 
were observed in patients who underwent axillary lymph node dissection vs. patients who did not 
have an axillary lymph node dissection (41 % vs. 11%, Chi-squared test P<0.01).  












































































































































































































































































































































































































































































































































































































































































































































This retrospective cohort study revealed that ~36% of patients suffered from varying degrees 
of pain 6 months after breast cancer treatment. We identified age and BMI as independent risk 
factors for persistent postoperative pain development. A 1 kg/m2 increase in BMI was associated 
with an OR of 1.04 (95%-CI:1.00-1.08). A 1 year increase in age was associated with an OR of 
0.97 (95%-CI:0.95-0.99). The secondary findings were consistent with the primary findings: a 
higher BMI was associated with a lower function score, higher symptom score and a lower total 
quality of life score. Additionally, a significant percentage of patients were found to be suffering 
from lymphedema following breast cancer treatment. 
Age
Younger age is commonly referred to as a predictive factor of persistent pain after breast 
cancer surgery. Consistent with our study, younger age has been shown to be associated with 
development of persistent pain after breast cancer treatment as well as higher pain intensity.11 It 
is unclear whether this is caused by a physiological difference in pain perception, by a difference 
in subjective expression, or a difference in daily physical activities compared to older patients.21 
 
BMI
In concordance with our results, two other large studies recently identified BMI as a potential 
risk factor for persistent pain. Meretoja et al. conducted a prospective cohort study analyzing 
860 women who underwent treatment for breast cancer and using a univariable analysis found 
BMI to be potentially associated with persistent pain at 12 months after surgery.14 However, in a 
multivariable ordinal logistic regression similar to our model, BMI did not predict persistent pain. 
Similarly, Miaskowski et al. analyzed 398 patients with persistent pain at 6 months.  Pain was 
classified as mild, moderate or severe. Patients with severe pain had a higher BMI in comparison 
to the patients that were mildly affected.15 However, one must consider that their analysis was 
purely univariable.
In an earlier retrospective cohort study of 196 women undergoing breast cancer surgery by 
Fecho et al. acute pain, pain at 1 month and at 6-12 months postoperatively was assessed.22 In 
a univariable analysis clinically obese (BMI >30) subjects were identified to have higher levels of 
mean pain during the first postoperative month and a trend was described toward higher mean 
pain levels at 6-12 months postoperatively. Smith et al. also performed a retrospective cohort 
study in 511 women undergoing breast cancer surgery and assessed persistent postsurgical 
pain,23 which was defined as any pain persisting beyond 3 months postoperatively. Their 
univariable analysis showed a trend towards increased persistent postsurgical pain in women 
with higher BMI, and found women with persistent pain to be significantly heavier and taller. 
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Our study is the first to report a relationship in a multivariable adjusted model between higher 
BMI and persistent pain following breast cancer treatment. It is important to note however, that 
the increased risk per 1 kg/m2 is relatively modest (~4%), in agreement with the risk reported by 
Meretoja et al..14  
A possible explanation for the relationship between BMI and persistent postsurgical pain may 
be that in patients with a high BMI axillary clearance is more challenging because of a greater 
amount of fatty tissue. Theoretically, this could affect the handling of the intercostobrachial 
nerve and thereby be subject to a potentially higher risk of pain and sensory disturbances.24 
Additionally, wound infection following breast cancer surgery has been shown to be associated 
with a higher BMI.25 Another explanation for the relationship of BMI to persistent postsurgical 
pain may be that obesity is linked to persistent postsurgical pain through low-grade inflammation 
and sensitized central pain modulation by the release of pro-inflammatory and insulin resistance-
inducing substances from visceral adipose tissue. Observational studies have showed that 
obese people exhibited decreased pain threshold to electrical stimuli as well as mechanical 
stimuli.26,27 In fibromyalgia, BMI is significantly related to the number of positive tender points 
(painful tender points upon palpation) as well as pain ratings of the tender points.28 Experimental 
studies with endotoxemia, in which a small dose of lipopolysaccharide is injected into volunteers, 
demonstrated a possible role of inflammation in pain sensitization. In one study, intravenous 
lipopolysaccharide injected in healthy participants induced reduced pain thresholds after 3 hours 
and these reductions were associated with peak increases in serum pro-inflammatory cytokine 
levels.29 Similarly, another study in healthy participants found that intravenous lipopolysaccharide 
reduced visceral pain thresholds (measured by rectal distension) two hours post injection and 
that these reductions were correlated with IL-6 increases in blood.30 
Pathways accounting for a pain-BMI association may also be bidirectional. For example, pain 
may lead to decreased physical activity, depression, and subsequent obesity. Additionally, 
persistent pain may lead to stress and cortisol secretion that contributes to truncal obesity.31 
Conversely, the metabolic derangements of obesity may predispose to pain as outlined above. 
Obesity may also lead to psychological morbidity,32 which is an important risk factor for persistent 
pain after breast cancer surgery.13 These underlying relationships should be addressed in future 
longitudinal studies. 
Other risk factors
In addition to age and BMI, the univariable analyses identified surgery type, radiotherapy, 
axillary lymph node dissection, chemotherapy, reoperation, and histopathological disease 
stage as potential risk factors for persistent pain. This is consistent with previous studies. 
Lumpectomy has been shown to be associated with persistent postsurgical pain and  this 
relationship seems to be influenced by its combination with radiotherapy,33,34 which is the 
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standard of care if breast conserving surgery is performed.34 Radiotherapy may cause persistent 
postsurgical pain through neuropathy and neuropathic pain.35 Axillary lymph node dissection 
has been found to be associated with persistent postsurgical pain in some studies,3,36 and this 
relationship may be mediated by nerve damage to the intercostobrachial nerve in the axilla.24 
Axillary lymph node dissection is also often combined with chemotherapy, and chemotherapy 
is associated with persistent postsurgical pain through neurotoxicity,37 which is a side effect 
of many chemotherapeutic agents used in the treatment of breast cancer such as taxanes, 
platinum agents and vinca alkaloids.38 Reoperation has been shown to be related to persistent 
postsurgical pain,39 which is likely an effect of the added risk of each individual surgery, but 
reoperation is often also combined with chemotherapy which may further increase the risk of 
persistent pain development. Histopathological disease stage may be related to persistent 
postsurgical pain through its relationship with several of the aforementioned factors,14 because 
locally more advanced disease warrants more extensive treatments with more tissue damage 
and a greater need for adjuvant treatments. When we stratified patients into age groups ≤50 and 
>50 in our study we found that younger women had higher grade tumors, which is consistent 
with literature.40 As a result of this difference in disease stage younger women underwent more 
extensive treatments, as indicated by higher rates of mastectomy, axillary lymph node dissection, 
reoperation and chemotherapy. We hypothesize that this distribution of disease stage, as well 
as the aforementioned interrelations between different treatment modalities, may have led 
to non-significant relationships of certain risk factors with persistent pain development in the 
multivariable model.   
The remaining risk factors that we assessed (i.e. smoking, diabetes, and hormone therapy) did 
not show a potential association with persistent pain in the univariate analyses. We included 
these factors based on circumstantial evidence that they could be related to persistent pain 
development after breast cancer treatment. Smoking was included because it is a known risk 
factor for chronic pain development outside the surgical context and chronic exposure to cigarette 
smoke may change pain perception in smokers compared with nonsmokers.41,42 Diabetes can 
cause neuropathic pain and has been shown to be associated with persistent postsurgical pain 
after hip and knee replacement.43 Hormone therapy consists of selective estrogen receptor 
modulators or aromatase inhibitors and these drugs are both known to induce musculoskeletal 
pain,44 which is not directly related to persistent postsurgical pain, but could have contributed to 
overall generalized pain. 
Quality of life
Consistent with our primary analysis, we found BMI to be associated with poorer quality of life 
scores after breast cancer treatment. We also found diabetes, axillary lymph node dissection, 
chemotherapy, and disease stage to be associated with poorer quality of life scores. Axillary 
lymph node dissection, chemotherapy and disease stage have previously been reported to 
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be associated with poorer quality of life after breast cancer treatment.36,45 Outside the surgical 
context, higher BMI46 and diabetes have been shown to negatively impact quality of life.47  
Lymphedema
In the literature, lymphedema has been reported to affect between 4 and 49% of patients treated 
for breast cancer.11 Lymphedema is dependent on several pre-, intra- and post-operative factors 
such as age, BMI, type of surgery and adjuvant therapy. We found ~22% of patients suffer 
from lymphedema which is thus consistent with literature, although there are different ways of 
measuring this complication.
Clinical implications
It is widely recognized that younger age is associated with a higher risk of developing persistent 
postsurgical pain. Although this fact may be used in preoperative risk assessments and 
postoperative preventative treatment plans, age itself is obviously not amenable to treatment. 
BMI, however, may constitute a possible treatment target but the potential benefits of weight loss 
as a strategy for reducing or preventing persistent postsurgical pain have to be demonstrated. At 
present, there is limited research assessing the effects of weight loss and exercise programs on 
generalized pain in obesity. One investigation used a physical therapy program prior to entering 
a weight management program and assessed mean body pain.48 The weight management 
protocol included daily caloric restriction to 1,200–1,800 kcal/day and multimodal exercise three 
times per week. Patients receiving the intervention reported a reduction in mean body pain of 
56%. Outside the pain specific literature, alternate day caloric restriction has been shown to 
cause clinical improvement and reduce systemic markers of inflammation and oxidative stress 
in obese asthmatic patients,49 which may also benefit sensitized central pain processing. 
Additional research should examine the effect of dietary and physical therapy programs on 
persistent postoperative pain conditions. This information could help clinicians determine the 
best strategy to manage or prevent pain in obese patients. In our specific population, female 
breast cancer patients undergoing cancer treatment, recommendations to restrict calories must 
take into consideration whether weight loss is possible during treatments such as chemotherapy. 
Moreover, breast cancer surgery can obviously not be postponed to allow for preoperative 
weight loss. 
Interestingly, obesity is associated with poorer breast cancer survival, and this relationship 
between BMI and survival is observed both in preoperative studies and postoperative studies 
(>12 months).50 Fasting is currently being assessed as a method to ameliorate side effects 
of chemotherapy and to improve response to chemotherapy and radiotherapy.51,52,53 In this 
context, there has been a call for randomized clinical trials to test interventions for weight loss 




Our study has some limitations that should be considered when interpreting the results. First, this 
was a retrospective study, and as such it is vulnerable to several types of bias. Misclassification 
bias may be of particular concern because the association between surgery and pain was based 
on patient reports. Secondly, we stratified patients into different ordinal categories according to 
their reported VAS scores and found the distribution skewed towards lower VAS scores. It is thus 
important to realize that most patients affected by the problem of persistent pain following breast 
cancer treatment report relatively mild pain scores and the ‘moderate pain/severe pain’ group 
constitutes a smaller percentage of the total population of patients after breast cancer treatment 
who report persistent pain.    
CONCLUSIONS
Younger age and higher BMI may be risk factors for persistent postoperative pain after breast 
cancer treatment. Higher BMI may also be associated with lower quality of life following breast 
cancer treatment. Taken together, BMI may be a target for preventative strategies in the context 
of persistent postsurgical pain. 
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Persistent postsurgical pain (PPSP) is a common complication of surgery that significantly 
affects quality of life. A better understanding of which patients are likely to develop PPSP 
would help to identify when perioperative and postoperative pain management may require 
specific attention. Quantitative sensory testing (QST) of a patient’s preoperative pain perception 
is associated with acute postoperative pain and acute postoperative pain is a risk factor for 
PPSP. The direct association between  preoperative QST and PPSP has not been reviewed to 
date. In this systematic review, we assessed the relationship of preoperative QST to PPSP. We 
searched databases with components related to (1) preoperative QST; (2) association testing; 
(3) PPSP. Two authors reviewed all titles and abstracts for inclusion. Inclusion criteria were: (1) 
QST performed prior to surgery; (2) PPSP assessed at least 3 months postoperatively; (3) the 
association between QST measures and PPSP is investigated. The search retrieved 905 articles; 
24 studies with 2,732 subjects met inclusion criteria. Most studies (22/24) had moderate to 
high risk of bias in multiple quality domains. 14 (58%) studies reported a significant association 
between preoperative QST and PPSP. Preoperative temporal summation of pain (four studies), 
conditioned pain modulation (three studies), and pressure pain threshold (three studies), showed 
the most frequent association with PPSP. The strength of the association between preoperative 
QST and PPSP varied from weak to strong. Preoperative QST is variably associated with PPSP. 
Measurements related to central processing of pain may be most consistently associated with 
PPSP. 
Key words: Quantitative sensory testing; Pain; Postoperative; Systematic review




QST:   Quantitative sensory testing
PPSP:   Persistent postsurgical pain 
CPM:   Conditioned pain modulation
PRISMA:  Preferred reporting items for systematic reviews and meta-analyses
PROSPERO:  International prospective register of systematic reviews
QUIPS:   Quality in prognosis studies
WDT:   Warm detection threshold
HPT:   Heat pain threshold
STHPI:   Suprathreshold heat pain intensity 
CDT:   Cold detection threshold
CPT:   Cold pain threshold
STCPI:   Suprathreshold cold pain intensity
EDT:   Electrical detection threshold
EPT:   Electrical pain threshold 
EPTT:   Electrical pain tolerance threshold
TSP:   Temporal summation of pain
VAS:   Visual analogue scale
NRS:   Numerical rating scale
WOMAC:  Western Ontario and McMaster Universities osteoarthritis index 
AAS:   Activity assessment scale




Chronic pain after surgery, referred to as persistent postsurgical pain (PPSP), is a condition 
leading to significant disease burden and reduced quality of life in affected individuals.1 PPSP 
is typically recognized as pain that: 1) lasts >3 months after surgery; 2) was not present before 
surgery or has different characteristics or increased intensity compared to preoperative pain; 3) 
is localized to the surgical site or a referred area; and 4) cannot be attributed to other causes.2-4 
The condition is common, with incidence estimates ranging from 10% to 50% of all postsurgical 
patients.2,5 PPSP can occur after any type of surgical procedure, but high-risk procedures include 
breast surgery, thoracotomy, limb amputation, and inguinal hernia repair.2,5 PPSP is relatively 
refractory to treatment,6 and a better understanding of which patients are likely to develop PPSP 
would help to identify those patients in whom perioperative and postoperative pain management 
may require special attention.3
Quantitative sensory testing (QST) refers to the recording of the sensation to different 
standardized stimuli to obtain measures of sensory processing. Testing is typically performed 
on skin, mucosa, or muscle tissue, and stimuli can include heat and cold, pressure, pinprick, 
vibration or electrical current.7,8 To test endogenous analgesia (conditioned pain modulation), 
pain perception can be measured before and after the application of a conditioning stimulus.9 
Another presumed measurement of central pain processing is the temporal summation of pain 
(‘wind-up’ phenomenon10), which is measured by determining the perception of pain to a brief 
series of repetitive stimuli.11
 
Previous systematic reviews have found that patients who preoperatively perceive more pain 
on QST (hyperalgesia) or have impaired endogenous analgesia,  experience more acute 
postoperative pain.12,13 Higher acute post-operative pain has been shown to be a risk factor for 
the development of PPSP.5,14 Along these lines, it has been suggested that preoperative QST may 
be useful to predict PPSP clinically.15 However, the specific relationship between preoperative 
QST and PPSP has not been systematically reviewed to date. 
Because of the strong relationship between preoperative QST measures and acute postoperative 
pain,12 we hypothesized that preoperative QST measures are strongly associated with PPSP.  The 
aim of this study was to systematically review the literature on the relationship of preoperative 
QST measures with PPSP development. If preoperative QST measures have a strong association 
with PPSP outcome, this would facilitate targeted studies on perioperative and postoperative 
pain management strategies to assess if PPSP can be prevented in individuals at high risk. 




The systematic review was conducted according to Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines.16 The protocol was registered in the 
International Prospective Register of Systematic Reviews (PROSPERO)17 under registration 
number: CRD42020137545. 
Literature Search 
On December 30th of 2019, we searched Medline and EMBASE for indexed original articles 
investigating the association between preoperative QST measures and PPSP using a search 
string including elements of QST, association testing, and PPSP. The structured search strategy 
was designed in Medline before the final search and subsequently applied to EMBASE. The full 
search strategy is available in Supplementary Table 4. The reference lists of the included studies 
were reviewed for additional relevant studies. 
Studies were included if (1) study design was prospective, (2) QST was performed prior to 
surgery, (3) PPSP was assessed at least 3 months after surgery, and (4) the association between 
QST and PPSP was investigated using correlation or regression analysis. We used the inclusion 
criterion regarding correlation or regression analysis because correlation and regression 
analyses provide information on association of QST with PPSP, whereas a comparison of mean 
QST values (patients with PPSP vs. without PPSP) does not. Studies were excluded only if the 
manuscript was not published in English. No restrictions were placed on the population of study, 
because no studies to date have clearly demonstrated that preoperative QST is more informative 
of postoperative pain in the context of a particular surgery type over another.12,18 
Studies using QST with any type of a controlled sensory stimulus were included as well as studies 
including measurements of conditioned pain modulation and temporal summation of pain. We 
included studies using outcomes exclusively measuring pain (e.g. visual analogue scale [VAS],19 
numerical rating scale [NRS]19), as well as studies in which PPSP was assessed by means of 
pain associated functional impairment (e.g. Western Ontario and McMaster Universities Arthritis 
Index [WOMAC],20 and Activity Assessment Scale [AAS]21). Our rationale for including both types 
of outcome measures was that PPSP is assessed by many research groups22-26 in terms of its 
impact on functioning, and a comprehensive assessment of PPSP is in line with our clinical 
vision on the diagnosis of PPSP and its treatment.27 
Study Selection 
Two reviewers (NvH and HMA) independently screened for eligible studies by assessing title 
and abstract. If one reviewer deemed a study potentially relevant for inclusion, the full text 
was assessed for eligibility. Subsequently, all full texts were assessed for inclusion. In case of 
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a disagreement, consensus was reached through discussion between the two reviewers. If 
consensus was not reached upon initial discussion, a third reviewer (HT) was consulted, which 
led to agreement in all assessments.
Data Extraction
Predefined data extraction included primary author, country of investigation, year of publication, 
sample size, demographic information, surgical procedure, type of QST measurement(s), 
method of QST measurement(s), PPSP outcome, statistical analysis method(s), and the results 
from association testing between pre-operative QST and PPSP. Association strength between 
pre-operative QST and PPSP was classified as weak ([-]0.1 to [-]0.3), moderate ([-]0.3 to [-]0.5), 
or strong ([-]0.5 to [-]1.0) based on the correlation coefficient or coefficient of determination. For 
coefficients of determination we calculated the square root (R) of the coefficient of determination 
(R2) for classification of the strength of association. 
Quality Assessment
Hayden et al. previously identified six important areas when evaluating validity and bias in 
studies of prognostic factors: study participation, study attrition, prognostic factor measurement, 
confounding measurement and account, outcome measurement, and analysis and reporting.28 
The refined version of the Quality In Prognosis Studies (QUIPS) tool29 (Supplementary Table 5), 
based on the aforementioned six factors, was employed to evaluate study quality in the present 
review. The QUIPS tool is widely used in the context of pain research.30-34 Initial assessments of all 
studies were made independently by two reviewers (NvH and HMA). In case of a disagreement 
in quality assessment, consensus was reached through discussion between the two reviewers. 
If consensus was not reached upon initial discussion, a third reviewer (HT) was consulted, which 
led to agreement in all assessments. 
Data Analysis Plan
We planned to perform a systematic review by descriptively presenting the results of the source 
studies per type of surgery. Meta-analysis was not anticipated because there is no globally 
accepted standardized QST measurement protocol and methods are known to vary substantially 
between research groups.35 
RESULTS
Included studies 
The systematic literature search identified 905 studies. 24 studies22-26,36-54 with a total of 1551 
female and 1302 male subjects were included in this review – Figure 1 & Supplementary Table 
1. There were 10 studies on orthopedic surgery,22-24,38-44 four on gynecological surgery,36,37,49,52 
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three on abdominal surgery,25,45,53 two on thoracic surgery,46,54 two on lumbar discectomy,26,48 one 
on breast cancer surgery,47 one on limb amputation,50 and one study on carpal tunnel release.51 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta Analyses16 flow diagram. 
Demographic, clinical data, tested QST-variables, and main findings are presented in 
Supplementary Table 1. There was substantial heterogeneity in QST measurement methods and 
detailed QST methods per study are described in Supplementary Table 2. 
Quality Assessment
Quality assessment of the included studies is presented in Supplementary Table 3. Reviewers 
initially agreed on 80% of the assessments and consensus was subsequently reached for all 
studies. The six bias domains included in the QUIPS quality assessment tool for the 24 studies 
(24 × 6 = 144 scores in total) were deemed to be at low risk for bias 54 times (37.5%), of 
moderate risk for bias 74 times (51.4%), and at high risk for bias 16 times (11.1%). 
Orthopedic Surgery
There were 10 studies in orthopedic surgery (in total 665 males and 830 females) that reported a 
correlation or regression analysis between preoperative QST measurements and PPSP22-24,38-44 – 
Supplementary Table 1 & Figure 2. The mean age of patients in these studies ranged from 45 to 
69 years. Seven studies reported on total knee replacement surgery,22,38-43 two studies reported 
on both total knee replacement surgery and total hip replacement surgery,23,24 and one study 
reported on shoulder surgery.44 A variety of QST modalities were used (Supplementary Table 
2) including electrical,38 cold,39,42,44 heat,22,39,42,44 pressure,22-24,39-41,43 and mechanical (pinprick) 
stimulation,44 as well as measurements of conditioned pain modulation40,41,43 and temporal 
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Figure 2. Number of studies with significant associations between preoperative quantitative sensory testing 
and persistent postsurgical pain across different surgical sub-types. 
summation of pain.40-42 Of the 10 studies, seven reported a significant correlation or association 
between preoperative QST and PPSP.22,23,38,40-43 Six out of these seven studies were conducted in 
total knee replacement surgery patients. Preoperative conditioned pain modulation,43 temporal 
summation of pain,40,42 as well as electrical,38 heat,42 and pressure22,40 thresholds were found to 
be associated with PPSP assessed at 6 – 18 months after surgery. One study that assessed 
preoperative pressure pain thresholds both in total knee and total hip replacement surgery found 
an association with pain 12 months after surgery in the hip replacement cohort, but not in the 
knee replacement cohort.23 Different outcomes of PPSP in the analyses of studies with significant 
findings included: a binary outcome of less or more than 1 mm on 100 mm VAS pain at 18 
months postoperatively,38 the continuous VAS pain score at 12 months postoperatively,40,42 the 
percentage difference between preoperative and 12 month postoperative pain on VAS,41 the 
percentage difference between preoperative and six month postoperative NRS pain score,43 
and a WOMAC 0-20 Pain subscale converted to a 0-100 scale at 12 months postoperatively.22,23 
The reported strength of the relationships of preoperative QST with PPSP ranged from weak to 
strong (Supplementary Table 1). Four out of seven studies that reported significant relationships 
in univariable analyses also found significant relationships in a multivariable analysis.23,38,41,42 
These studies found significant relationships between preoperative temporal summation of pain, 
pressure pain threshold, or electrical pain threshold and PPSP. 
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Gynecological Surgery       
There were four studies in gynecological surgery (in total 400 patients) that reported a correlation 
or regression analysis between preoperative QST measurements and PPSP – Supplementary 
Table 1 & Figure 2.36,37,49,52 The mean age of patients in the gynecological surgery studies ranged 
from 24 to 49 years. Two studies reported on hysterectomy,36,52 one reported on laparoscopy for 
the indication of pelvic pain,49 and one study included vestibulectomy patients.37 QST measures of 
heat,37 pressure,36 and mechanical (pinprick) stimulation49 were used, as well as a measurements 
of temporal summation of pain36,52 – Supplementary Table 2. Two of the four studies reported a 
significant association with PPSP. Preoperative measurement of temporal summation of pain 
was related to pain six months after hysterectomy52 and  tonic heat pain was found to be related 
to pain improvements in vulvar pain during intercourse eight months after vestibulectomy.37 In 
the latter study improvement was defined as a binary outcome with at least a 30% perceived 
positive change; a 1 mm lower score on a 100 mm VAS during heat pain was associated with an 
odds ratio of 1.03 (95% CI: 1.004 – 1.065) of achieving this outcome.37 In the hysterectomy study 
PPSP was defined as a pain score ≥3 on the NRS at six months postoperatively and stepwise 
increments in preoperative temporal summation of pain were associated with this outcome in a 
multivariable model (OR 1.078, 95% CI: 1.041 – 1.117).52  
Abdominal Surgery 
There were three studies in abdominal surgery (in total 458 males and 14 females, skewed 
gender balance because of a large hernia repair study) that reported a correlation or regression 
analysis between preoperative QST measurements and PPSP25,45,53 – Supplementary Table 
1 & Figure 2. One study assessed hernia repair surgery (open or laparoscopic),25 one 
study assessed laparoscopic triple neurectomy surgery,45 and one study assessed open 
gastrointestinal surgery.53 The mean age of patients in these studies was comparable (55,25 47,45 
and 5353 years, respectively). Preoperative QST measurements consisted of electrical,53 cold,45 
heat,25,45 pressure45,53 and mechanical (pinprick) stimulation,45 and measurements of conditioned 
pain modulation53 and temporal summation of pain45 were used as well – Supplementary Table 
2. Two of the three studies reported statistically significant relationships between preoperative 
QST measurements and PPSP.25,53 Conditioned pain modulation before gastrointestinal surgery 
demonstrated a strong correlation (Pearson correlation, r = 0.68, P = 0.02) with pain on visual 
analogue scale 6 months postoperatively.53 Tonic heat pain intensity before hernia repair surgery 
was related to PPSP six months postoperatively (OR in multivariable model: 1.3, 95% CI: 1.2 – 
1.6).25 This odds ratio represents a per point change on a 0 – 10 pain scale during tonic 47 °C 
stimulation with a binary outcome of PPSP at 6 months postoperatively, which was defined as a 
score of  ≥ 8.3 on the Activity Assessment Scale, which indicates moderate or severe impairment 




Two of the included studies were conducted in thoracic surgery patients (in total 80 males and 
24 females).46,54 Grosen et al.46 studied 42 young males (average: 19 years, range: 17 – 23 
years) undergoing minimally invasive pectus excavatum repair while Yarnitsky et al.54 studied 
older thoracotomy patients (mean: 62 years, standard deviation: 14 years). Grosen et al. 
performed pressure QST testing and conditioned pain modulation testing, whereas Yarnitsky et 
al. performed thermal QST measures and conditioned pain modulation testing. A relationship 
between preoperative conditioned pain modulation and postoperative pain seven months after 
thoracotomy was found in the latter study in a multivariable logistic regression model. Conditioned 
pain modulation was calculated as the difference in pain rating between two identical 30-second 
heat stimuli on the volar forearm, either with or without immersion of the contralateral hand 
in a hot water bath (the conditioning stimulus). Conditioned pain modulation was expressed 
as ‘efficiency’, meaning that a reduction in pain rating during the conditioning stimulus was 
expressed as a positive value. A higher level of conditioned pain modulation efficiency was 
associated with an odds ratio of 0.52 (95% CI, 0.33–0.77) for PPSP, indicating a halved risk per 
10-point step on the -100 to 100 conditioned pain modulation efficiency scale. It is unclear if and 
what specific cut-off score was used to define if a patient was suffering from PPSP at the long-
term follow-up visit.  
Lumbar Discectomy 
Two of the included studies were conducted in lumbar discectomy patients (in total 53 males 
and  39 females).26,48 Patients were of comparable age between these two studies (mean age of 
4048 and 3826 years). Both studies used a microscopic surgical technique for the discectomies. 
Hegarty et al.48 performed electrical QST testing, whereas Nygaard et al.26 performed cold 
and heat QST measurements, as well as measurements of vibration perception threshold. In 
a univariate analysis, Nygaard et al. found a relationship of modest strength (R2 = 0.13, P = 
0.03) between baseline warm detection threshold and a composite clinical overall score55 that 
included pain, symptoms and signs at one year after surgery, whereas Hegarty et al. did not find 
any significant associations. 
Other Surgery 
The remaining three studies included patients undergoing breast cancer surgery (124 females, 
mean age 57 years),47 limb amputation (14 females / 21 males, mean age 71 years),50 and 
carpal tunnel release (106 females / 25 males, mean age 54 years).51 Using a multivariable 
analysis, the study by Roh et al.51 identified a modest relationship (partial R2 = 0.11, P = 0.02) 
between preoperative pressure pain thresholds at the midvolar forearm and NRS pain scores 
three months after carpel tunnel release. This relationship was not found with the 6 or 12-month 
follow-up pain scores. The studies in breast cancer surgery and limb amputation patients did not 
report significant associations between preoperative QST and PPSP.   
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Integration of Results across all Surgery Sub-Types 
Across all 24 studies in all surgery subtypes, 14 (58%) found a relationship between preoperative 
QST measures and persistent postsurgical pain22,25,26,38,40-43,51-54 – Supplementary Table 1 & Figure 
2. Most significant associations were found in studies in orthopedic surgery,22,38,40-43 followed by 
gynecological37,52 and abdominal surgery,25,53 thoracic surgery,54 lumbar discectomy,26 and carpal 
tunnel release.51 The QST measures most frequently associated with PPSP included temporal 
summation of pain (four studies40-42,52), conditioned pain modulation (three studies43,53,54), pressure 
pain threshold (three studies22,23,51), followed by warm detection threshold (two studies26,42), 
electrical detection threshold (one study38), electrical pain threshold (one study38), and tonic pain 
(one study37) – Supplementary Table 1 & Figure 3. Temporal summation of pain was the only 
Figure 3.  Number of studies with significant associations between preoperative quantitative sensory testing 
and persistent postsurgical pain across different quantitative sensory testing measures. 
QST parameter with more significant than non-significant associations with PPSP in the different 
studies in which it was tested.36,40-42,45,47,52 The strength of the relationship between preoperative 
QST and PPSP was extracted from only nine studies, because five studies only reported odds 
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ratios.25,37,52,54 The strength of the associations was equally distributed across the predefined 
weak,40-42 moderate,22,26,51 and strong categories.38,43,53 QST parameters with weak, moderate, 
and strong associations with PPSP are displayed in Supplementary Table 1 & Figure 4. 
Figure 4. Association strength between pre-operative quantitative sensory testing and persistent postsurgical 
pain. Associations were classified as weak ([-]0.1 to [-]0.3),40-42 moderate ([-]0.3 to [-]0.5),22,26,51 or strong ([-
]0.5 to [-]1.0)38,43,53 based on the reported correlation coefficient or coefficient of determination.   
DISCUSSION
Principal Findings
Our study adds to prior existing work by providing a systematic literature review assessment 
of the specific relationship between preoperative QST measures of pain processing and the 
development of persistent postsurgical pain. QST was found to be variably associated with 
persistent postsurgical pain. The significant associations that were reported occurred in different 
surgical populations and for various QST measures. Pressure pain thresholds, conditioned 
pain modulation, and temporal summation of pain were among the most frequently persistent 
postsurgical pain associated QST measures.  92% of the included studies22-24,26,37-54 were found 
to have moderate or high risk of bias in multiple quality domains. 
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Comparable Systematic Reviews 
Werner et al.12 conducted a systematic review on the prediction of postoperative pain using 
preoperative QST. They included both studies with acute and late endpoints; of the 14 studies 
included, two reported on PSPP (>3 months after surgery).38,54 Their main conclusions were: 
1) Preoperative QST may predict 4-54% of the variance in acute postoperative pain depending 
on the stimulation modality and the testing paradigm; 2) The predictive strength of individual 
preoperative QST factors for acute postoperative pain is higher than the previously reported 
single demographic or psychological risk factors; 3) Increased preoperative sensitivity on QST 
may be associated with a higher risk of PPSP development. We focused exclusively on the 
association between preoperative QST and PPSP in this review and 18 out of 24 studies were 
published after the review by Werner et al.. The two PPSP studies included in the Werner et al. 
review both reported very substantial odds ratios of PPSP development (9.238 and 0.5254) with 
stepwise changes in preoperative QST measures. In contrast to Werner et al., we systematically 
assessed the strength of association between preoperative QST and PPSP through evaluation of 
correlation coefficients and coefficients of determination and found the associations in positive 
studies to be weak,40-42 moderate,22,26,51 and strong38,43,53 in similar frequencies.  
Recently, Sangesland et al.18 conducted a systematic review on the relationship between 
preoperative QST measures and postoperative pain. They did not specifically study acute 
postoperative pain or PPSP, but 12 out of 30 (40%) of the studies included pain outcome 
measurements at time points consistent with PPSP.23,25,38-41,43,44,46,49,53,54 These studies were also 
identified in the present review. The main conclusions of the study by Sangesland et al. were: 
1) most studies showed moderate to high risk of bias; 2) most QST variables demonstrated 
no consistent correlation with pain after surgery; 3) QST measures assessing suprathreshold 
pain or measures of central processing such as conditioned pain modulation and temporal 
summation of pain showed the most promising correlations. The study did not report specific 
conclusions related to the association of preoperative QST measures with PPSP, but the overall 
variable relationship between preoperative QST measures and postoperative pain is in line with 
our results. Consistent with the reported conclusion on measures of central processing of pain 
being most associated with postoperative pain, we found that conditioned pain modulation and 
temporal summation of pain were among the most frequently PPSP associated QST measures. 
Contrary to the reviews by Werner et al.12 and Sangesland et al.,18 our study was the first to 
focus exclusively on the relationship between preoperative QST and PPSP. Several important 
studies on the relationship between preoperative QST and PPSP have been published since the 
reviews by Werner et al. and Sangesland et al..24,42,47,51,52 Additionally, our search was focused 
on PPSP specifically and revealed multiple earlier articles that were not identified in these prior 
reviews.22,26,36,37,45,48,50 Taken together, this allowed us to review 24 studies on the relationship 
between preoperative QST and PPSP, whereas Werner et al. and Sangesland et al. included 2 
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and 12 studies assessing this relationship, respectively. Importantly, we found that only 58% of 
studies found a significant relationship between different preoperative QST measures and PPSP. 
The strength of this relationship varied from weak to strong.  The findings of this review thus do 
not support the use of QST in clinical care at present to predict PPSP in patients scheduled for 
surgery. 
Neither our review, nor the reviews by Werner et al.12 or Sangesland et al.18 were designed to 
assess if there is a difference in association between preoperative QST measures and acute 
postoperative pain vs. preoperative QST measures and PPSP. However, the overall findings from 
the three studies suggest that the relationship between preoperative QST and pain is stronger at 
earlier time points after surgery vs. later ones. Werner et al. included mostly studies concerning 
acute postoperative pain and found many strong relationships between preoperative QST and 
postoperative pain. On the other hand, Sangesland et al. included a substantial amount of 
studies with PPSP endpoints and found mixed results, consistent with the present study focusing 
on PPSP exclusively. Early postoperative pain is believed to be an important risk factor for PPSP. 
The transition of acute postoperative pain to PPSP has been attributed to neuroplastic changes 
in the dorsal horn, reorganization of brain structures and connectivity, and/or loss of endogenous 
pain modulation.14 However the  association of acute postoperative pain with  PPSP and the 
strength of association may vary between surgical procedures.5,56  
Research and Clinical Implications
The results from this systematic review indicate that preoperative temporal summation of pain, 
conditioned pain modulation, and pressure pain threshold were most frequently associated with 
PPSP development. It is interesting to note that 10 out of the 14 studies that reported significant 
findings were conducted in populations who likely had experienced pain for a substantial time 
before surgery.22,23,26,37,38,40-43,51,52 It is possible that in these patients ongoing peripheral nociceptive 
input may have induced sensitization of central pain pathways preoperatively, thus allowing 
for preoperative QST to more effectively identify the patients at risk of PPSP development. A 
preoperatively sensitized central pain processing in these patients is illustrated by the associations 
of preoperative temporal summation of pain40-42,52 and conditioned pain modulation43,53,54 with 
PPSP in this review. Additionally, the significant associations between preoperative pressure pain 
threshold and PPSP that were found in three studies22,23,51 were consistent with preoperative central 
sensitization as well, considering that the pressure pain threshold was measured distant from the 
surgical site (volar forearm) in all studies (Supplementary Table 2). In a study by Wylde et al. in 
total knee prosthesis surgery patients, pressure pain thresholds were measured preoperatively 
both at the affected knee and the right volar forearm but only the forearm measurement was 
associated with WOMAC scores at one year postoperatively.22 Along these lines, it would seem 
worthwhile to focus future research efforts on preoperative QST measurements of central pain 
processing, especially in patients who have suffered from pain preoperatively for some time. 
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In patients who have not suffered from substantial pain preoperatively, early changes in pain in 
response to surgery (< 1 week after surgery) as assessed with QST may be more consistently 
associated with PPSP development.57 
Methodological considerations 
It is important to note that most of the studies in this review were found to have moderate or high 
risk of bias in multiple quality domains.22-24,26,37-54 The majority of studies in this review (20/24, 83%) 
did not assess a relationship between preoperative QST measures and PPSP as a prespecified 
primary hypothesis with an associated power calculation.22-26,36-45,48,50,52-54 Additionally, many 
studies assessed a multitude of relationships in a limited number of subjects. Although several 
studies reported using correction for multiple testing related to pairwise comparisons,39-41,43,44,53 
only one study reported a correction for multiple correlation testing.45 These conditions allow 
for the possibility that some negative findings concerning a relationship between preoperative 
QST and PPSP are type II errors or that some positive findings are type I errors.58,59 Finally, the 
associations in all studies were based on explanatory analyses in the entire study cohort without 
validation testing in an independent cohort. To establish any preoperative QST measurement as 
a clinically useful prospective predictor of PPSP future studies should either focus on validating 
previously established associations or include both model development and validation cohorts 
for analysis.60,61 Such studies would also help in assessing if there is potentially causality between 
findings on preoperative QST and PPSP development.    
A limitation that pertains to the present study is a lack of meta-analysis of relationships. 
QST methods vary widely between research groups, which limits the generalizability of our 
conclusions to the specific methods employed and their associations. We attempted to provide 
a comprehensive overview of the specific QST methods employed in each study through the 
supplementary materials to allow for identification of the exact stimulation modality, testing site, 
and testing paradigm in each included study. Harmonization of protocols across international 
research groups would assist in effective investigation of the association between preoperative 
QST and PPSP. Additionally, it would be helpful to consistently incorporate other risk factors 
that may be associated with PPSP, such as psychological factors,62 genetic susceptibility,63 
and preoperative pain64  in future protocols to assess if QST measures are truly independently 
associated with PPSP. 
CONCLUSION
Preoperative conditioned pain modulation, temporal summation of pain, and pressure pain 
threshold were most frequently significantly associated with persistent postsurgical pain with 
variable strengths of association. Most of the included studies were found to have moderate 
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or high risk of bias in multiple quality domains. To facilitate the potential use of preoperative 
quantitative sensory testing in clinical prediction of persistent postsurgical pain, high quality 
prospective studies with independent validation cohorts are warranted. 
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Supplementary Table 2. Detailed description of quantitative sensory testing methods for each included study. 
Study Measured QST variables Methods Descriptions
Orthopedic Surgery
Lundblad et al.38 EDT, EPT Instrument(s):  Pain Matcher (electrical stimulation) (Cefar 
Medical AB, Lund, Sweden) to expose the patient to an 
electrical stimulus.
Measurement(s): (1) first noticeable sensation, (EDT), 
(2) perceived signal was painful (EPT) and (3) when the 
intensity of pain was the same as that from their knee on 
movement (the matched pain). 
Location(s): The Pain Matcher is a handheld device and 
the current is applied between the thumb and index finger 
of the right hand.  
Martinez et al.39 CPT, HPT, PPT, STCPI, STHPI Instrument(s):  Von Frey hairs (Bioseb, Chaville, France) 
for punctate mechanical stimulation. Thermal sensations 
were assessed with a Somedic thermotest (Somedic AB, 
Stockholm, Sweden).
Measurement(s): (1) lowest pressure the patient 
considered painful, (2) perceived heat was painful, (3) 
perceived cold was painful, (4) perceived pain to heat 
stimulation above the pain threshold, and (5) perceived 
pain to cold stimulation below the pain threshold. 
Location: The operative knee, the contralateral knee, and 
the hand as a control site.  
Petersen et al.40 CPM, PPT, TSP Instrument(s):  A handheld pressure algometer (Somedic 
AB, Hörby, Sweden) was used to apply pressure. The cold 
pressor test was used as the conditioning pain stimulus for 
CPM measurements. The hand contralateral to the most 
affected knee was submerged in ice water (2°C, water 
stirred in ice). A von Frey stimulator with a weighted load 
(Aalborg University, Aalborg, Denmark) was used to induce 
temporal summation. 
Measurement(s): (1) perceived pressure was painful 
(PPT), (2) difference in PPT before and immediately after 
applying the conditioning stimulus (CPM) and (3) the pain 
intensity difference (TSP) between the first and the last 
stimulation of 10 consecutive stimulations with the von Frey 
stimulator. 
Location(s): Seven sites in the peripatellar region, 1 
control site on the tibialis anterior, and 1 control site at the 
extensor carpi radialis longus were used for both the knee 
osteoarthritis-affected and contralateral side. 
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Study Measured QST variables Methods Descriptions
Petersen et al.41 CPM, PDT, PPT, PPTT, TSP Instrument(s): Pressure stimulation was applied using a 
computer-controlled cuff algometer (NociTech and Aalborg 
University, Denmark) including a 13-cm wide tourniquet cuff 
(VBM, Sulz, Germany). A handheld algometer (Somedic 
AB, Sweden) was also used to apply pressure at different 
locations. The computer-controlled cuff was set to 60 
kPa to function as the conditioning stimulus for CPM 
testing and was also used as repeated stimulus for TSP 
measurement.
Measurement(s): (1) first perceived pressure from the cuff 
(PDT), (2) perceived pressure from the handheld algometer 
was painful (PPT), (3) highest pressure stimulation from 
cuff tolerable (PPTT), (4) difference in PDT before and 
during the conditioning stimulus (CPM), and (5) the pain 
intensity difference (TSP) between the average pain score 
over the four first and the last two cycles of 10 repeated 
mechanical pressure stimuli from the cuff. 
Location(s): The cuff was placed at the level of the head 
of the gastrocnemius muscle of the leg most affected by 
knee osteoarthritis. The handheld algometer was used 
for PTT testing on 7 sites at the most affected knee with 
2 distant sites at the tibialis anterior muscle and at the 
extensor carpi radialis longus muscle.
Petersen et al.42 CDT, CPT, HPT, WDT, TSP Instrument(s): Thermal stimulation was applied using 
the Medoc Pathway system (Medoc Ltd, Ramat Yishai, 
Israel). A von Frey stimulator with a weighted load (Aalborg 
University, Denmark) was used to induce temporal 
summation. 
Measurement(s): (1) first perceived cold sensation (CDT), 
(2) perceived cold was painful (CPT), (3) first perceived 
warmth sensation (WDT), (4) heat sensation was painful 
(HPT), and (5) the difference in the pain intensity between 
the first and the last stimulation of 10 repeated stimuli from 
the von Frey stimulator (TSP). 
Location(s): All assessments were performed on the 
tibialis anterior muscle.
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Study Measured QST variables Methods Descriptions
Vaegter et al.43 CPM, PPT, PPTT Instrument(s): A computer-controlled cuff (NociTech and 
Aalborg University, Denmark) with a 13-cm wide silicone 
tourniquet cuff (VBM, Sulz, Germany) was used to apply 
pressure. A handheld pressure algometer was used as 
well (Somedic Hörby, Sweden). The conditioning stimulus 
for CPM measurement was the cold pressor test (tank with 
circulating ice water at 1 to 2 ºC).
Measurement(s): (1) perceived pressure becomes painful 
(PPT, assessed both by cuff and handheld algometer), (2) 
highest pressure stimulation from cuff tolerable (PPTT), 
and (3) the percent change in manual and cuff algometery 
measurements during and immediately after conditioning 
stimulus vs. before the conditioning stimulus (CPM). 
Location(s): The cuff measurements were performed on 
the leg in which the patient previously had a total knee 
prosthesis implanted. The manual pressure measurements 
were performed in the middle of the quadriceps femoris 
muscle of the affected leg, in the middle of the quadriceps 
femoris muscle in the nonaffected leg, in the middle of the 
dominant biceps brachii muscle, and in the nondominant 
upper trapezius muscle. The foot of the nonaffected leg 
was submersed into the ice water bath for the CPM testing.
Valencia et al.44 CPT, HPT, MPT, STCPI, STHPI Instrument(s): Heat stimulation was applied using a 
contact heat evoked potential stimulator (Medoc Advanced 
Medical Systems, Ramat Yishai, Israel). Von Frey hairs 
(Bioseb, Chaville, France) were used to provide mechanical 
punctate pressure. A cold-water bath was used to provide 
the conditioning stimulus for CPM testing. 
Measurement(s): (1) perceived punctate pressure 
becomes painful (MPT), (2) perceived cold becomes 
painful (CPT), (3) perceived heat stimulation becomes 
painful (HPT), (4) perceived pain during cold stimulation 
5°C below the cold pain threshold (STCPI), and (5) 
perceived pain during heat stimulation 2°C and 4°C above 
the heat pain threshold (STHPI). 
Location(s): measurements were performed on the 
operated knee and proximal to the operated knee, as well 
as on the contralateral knee and the palm of the right hand. 
Wylde et al.22 HPT, PPT Instrument(s): A handheld algometer (Somedic, Sweden) 
was used to apply pressure. Heat stimulation was 
applied using a contact heat evoked potential stimulator 
(Thermotest Modular Sensory Analyzer, Somedic, Sweden).
Measurement(s): (1) perceive pressure stimulation 
becomes painful (PPT) and (2) perceived heat stimulation 
becomes painful (HPT). 
Location(s): The volar surface of the right forearm and 
the medial side of the operated knee were used for 
measurements.
Supplementary Table 2. Continued
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Study Measured QST variables Methods Descriptions
Wylde et al.23 PPT Instrument (s): A handheld algometer was used to apply 
pressure (Somedic, Hörby, Sweden). 
Measurement(s): (1) perceived pressure becomes painful 
(PPT). 
Location(s): Measurements were performed on the volar 
forearm contralateral to the painful lower limb. 
Wylde et al.24 PPT Instrument(s): A handheld algometer was used to apply 
pressure (Somedic, Hörby, Sweden). 
Measurement(s): (1) perceived pressure becomes painful 
(PPT).
Location(s): Measurements were performed on the volar 
forearm contralateral to the painful lower limb.
Gynecological Surgery 
Brandsborg et al.36 PPT, TSP Instrument(s): A handheld algometer was used to 
apply pressure (Somedic AB, Sweden) on the abdomen. 
A modified pressure algometer was used for vaginal 
examination. This palpometer, consisting of a force-sensing 
resistor (FSR151, Interlink Electronics, Inc.) connected to a 
meter, was attached to the index finger of the examiner with 
adhesive tape (Micropore). Repeated stimulation with a von 
Frey hair (Sensory evaluator, Stoelting Co., USA; No. 5.88, 
nominal buckling force 588.2 mN) was used to induce TSP. 
Measurement(s): (1) perceived pressure stimulation 
becomes painful (PPT) and (2) pain immediately after 30 
seconds of 2 Hz stimulation with the von Frey hair (TSP). 
Location(s): The midline external abdominal wall ~2 cm 
proximal to where a Pfannenstiel incision would be made 
and the ischial spines by vaginal exploration.
Granot et al.37 HPT, STHPI, TP Instrument(s): Heat stimulation was applied using a 
contact heat evoked potential stimulator (TSA-2001; 
Medoc, Ramat-Yeshai, Israel).
Measurement(s): (1) perceived heat stimulation becomes 
painful (HPT), (2) the perceived pain to 1 second heat 
stimulation at 47°C (STHPI), and (3) the perceived pain to 
1-minute stimulation at 46°C (TP). 
Location(s): All stimuli were applied to the volar forearm.
Jarrell et al.49 MPT Instrument(s): Mechanical punctate pressure was applied 
using a von Frey electro-anesthesiometer
(IITC Life Science, Woodland Hills, CA).
Measurement(s): (1) Perceived mechanical punctate 
pressure becomes painful (MPT). 
Location(s): Measurements were performed on the lower 
abdomen in the region of pelvic pain muscle tenderness.  
Supplementary Table 2. Continued
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Sng et al.52 TSP Instrument(s): A von Frey filament was used to provide 
repeated mechanical punctate pressure to induce TSP. 
Measurement(s): (1) The different in pain rating rating 
after the 10th touch vs. 1st touch with the von Frey filament 
(TSP).  
Location(s): Volar forearm. 
Abdominal Surgery 
Aasvang et al.25 HPT, TP, WDT Instrument(s): Heat stimulation was applied using a 
contact heat evoked potential stimulator (Modular Sensory 
Analyzer, Somedic AB, Hörby, Sweden). 
Measurement(s): (1) warmth stimulation is first perceived 
as warm (WDT), (2) when heat stimulation is perceived as 
painful (HPT), and (3) perceived pain to 45°C, 46°C, 47°C, 
and 48°C during 5 second intervals (TP).   
Location(s): Tests were performed 2 cm lateral to the 
pubic bone and 2 cm above the inguinal ligament (hernia 
area) as well as on and anterior on the ipsilateral forearm. 
Bjurstrom et al.45 CDT, CPT, HPT, MDT, MPT, PPT, 
PPTT, TSP, WDT
Instrument(s): Calibrated Semmes–Weinstein 
monofilaments were used to apply punctate mechanical 
stimulation (ranging from 2.83 to 6.65 log force; equivalent 
to 0.69 to 2,942 mN; North Coast Medical, Gilroy, CA, 
U.S.A.). A handheld algometer (Wagner Instruments, 
Greenwich, CT, U.S.A.) was used to apply pressure. Heat 
and cold stimulation was applied using a contact thermal 
stimulator (TSA-II Neurosensory Analyzer, Medoc Ltd., 
Ramat Yishai, Israel). A 5.07 log force monofilament for 
pinprick stimulation was used to induce TSP. 
Measurement(s): (1) the punctate mechanical stimulation 
is experienced as a sensation of touch (MDT), (2) the 
mechanical punctate stimulation is painful (MPT), (3) 
pressure stimulation is perceived as painful (PPT), (4) 
highest pressure stimulation tolerable (PPTT), (5) warmth 
stimulation is first perceived as warm (WDT), (6) heat 
stimulation is first perceived as painful (HPT), (7) cold 
stimulation is first perceived as cold (CDT), (8) cold 
stimulation is first perceived as painful (CPT), and (9)  the 
difference in the pain intensity between baseline and after 2 
Hz stimulation with the monofilament for 60 seconds (TSP).
Location(s): Testing was performed in 2 areas within 
the area with maximum pain on the affected side of 
postherniorrhapy pain, and a comparison control area on 
the contralateral side (corresponding to the most painful 
area on the affected side). 
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Wilder-Smith et al.53 CPM, EPTT, PPTT Instrument(s): Electrical stimulation was delivered using 
a computerized electric stimulation device (QST III, JNI 
Biomedical ApS, Klarup, Denmark) delivering electrical 
constant current stimulation via self-adhesive electrodes. A 
handheld algometer (Somedic AS, Horeby, Sweden) was 
used to apply pressure. An insulate bucket containing ice 
and water (0°C - 1°C) was used as cold pressor test and 
conditioning stimulation for CPM measurement. 
Measurement(s): (1) highest electrical stimulation 
tolerable (EPTT), (2) highest pressure stimulation tolerable 
(PPTT), and (3) the difference in electrical or pressure pain 
thresholds from baseline to immediately after immersion of 
hand in ice water for up to 180 seconds (CPM).    
Location(s): Measurements were performed 10 cm lateral 
to the midpoint of the planned surgical incision and in 
the L2 leg dermatome opposite to the planned side of 
operation.  
Thoracic Surgery
Grosen et al.46 CPM, PPT Instrument(s): A handheld algometer (Algometer, 
Somedic AB, Hörby, Sweden) was used to apply pressure. 
A stirred ice water bath (1±1ºC) was used as cold pressor 
test and conditioning stimulation for CPM measurement. 
Measurement(s): Pressure stimulation becomes painful 
(PPT) and (2) the difference in PPT before and immediately 
after immersion of the non-dominant hand in icewater for 
up to 120 seconds (CPM).  
Location(s): Pressure algometry was performed at the 
patients’ quadriceps muscle (rectus femoris) 10 cm above 
the patella on the same side as the dominant hand.
Yarnitsky et al.54 CPM, HPT, STHPI Instrument(s): Heat stimulation was applied using a 
contact heat evoked potential stimulator (TSA-2001, 
Medoc, Israel). Immersion of a hand in a hot water bath 
(46.5ºC) (Heto Cooling Bath, Jouan Nordic A/S, Allerod, 
Denmark) was used as the conditioning stimulus for CPM 
testing. 
Measurement(s): (1) heat stimulation is perceived as 
painful (HPT), (2) heat stimulation that induces a pain score 
of 60 on a scale 0-100 (STHPI), and (3) the difference in 
perceived pain to the previously found STHPI before and 
after immersion of the contralateral hand in a hot water 
bath for 1 minute.  
Location(s): Testing was performed on the volar forearm. 
Supplementary Table 2. Continued
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Lumbar Discectomy 
Hegarty et al.48 EDT, EPT, EPTT Instrument(s): Constant current electrical stimulation 
was applied using a Dantec Keypoint Neurodiagnostic 
stimulator with Dantec disposable surface electrodes 
(Natas Medical Instruments Inc, San Carlos, CA).
Measurement(s): (1) electrical stimulation is first detected 
(EDT), (2) electrical stimulation becomes painful (EPT), and 
(3) the highest electrical stimulation tolerable (EPTT). 
Location(s): Measurements were performed on the 
forearm (C8-T1 dermatome) contralateral to the nerve root 
involved, and in the affected dermatome of the affected 
and contralateral lower limbs.
Nygaard et al.26 CDT, WDT, VT Instrument(s): Thermal stimulation was applied using a 
contact thermal stimulator (Thermotest® type 1, Somedic 
AB, Sweden). Quantitative vibrametry was performed using 
the Vibrameter (Somedic, Sweden).
Measurement(s): (1) cold stimulation is first detected 
as cold (CDT), (2) warmth stimulation is firs perceived as 
warm (WDT), and (3) the first detection of vibration (VT). 
Location(s): Measurements were performed on the dorsal 
side of the first phalanx (L5 dermatome), or the dorsal side 
of the 5th metatarsal (S1 dermatome). 
Other Surgery 
Habib et al.47 CPM, STHPI, TSP Instrument(s): Thermal stimulation was applied using a 
contact thermal stimulator (medoc-TSAII, Medoc, Ramat-
Yishai, Israel). A 225.1-g von Frey filaments (No. 6.45) was 
used to provided repeated mechanical punctate stimulation 
to assess TSP.
Measurement(s): (1) heat stimulation that induces a pain 
score of 60 on a scale 0-100 (STHPI), (2) the difference in 
perceived pain to the previously found STHPI before and 
during immersion of the non-dominant hand in a hot water 
bath for 1 minute, and (3) the difference in pain rating 
between the 1st  1 second pinprick stimulation and the 
pain rating after the 10th touch.
Location(s): All measurements were performed on the 
dominant forearm. 
Nikolajsen et al.50 PPT Instrument(s): Pressure was applied using a hand-held 
electronic pressure algometer (Somedic AB, Sweden).
Measurement(s): (1) pressure stimulation becomes 
painful (PPT).
Location(s): Measurements were performed at the lateral 
aspect of the limb as close to the planned amputation line 
as possible.
Supplementary Table 2. Continued
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Roh et al.51 PPT Instrument(s): Pressure was applied using a handheld 
algometer (Somedic, Hörby, Sweden).
Measurement(s): (1) pressure stimulation becomes 
painful (PPT). 
Location(s):  Measurements were performed on the 
midvolar forearms. 
Supplementary Table 2. Continued
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Supplementary Table 4. Search strings used in PubMed and EMBASE.
Quantitative Sensory Testing 
1. Quantitative sensory testing [Title/Abstract] 12. Pressure pain tolerance[Title/Abstract]
2. Heat pain sensitivity [Title/Abstract] 13. Electrical pain sensitivity [Title/Abstract]
3. Heat detection threshold [Title/Abstract] 14. Electrical pain threshold [Title/Abstract]
4. Heat pain threshold [Title/Abstract] 15. Electrical pain tolerance[Title/Abstract]
5. Heat pain tolerance [Title/Abstract] 16. CPM [Title/Abstract]
6. Cold pain sensitivity[Title/Abstract] 17. Conditioned pain modulation [Title/Abstract]
7. Cold detection threshold[Title/Abstract] 18. DNIC [Title/Abstract]
8. Cold pain threshold[Title/Abstract] 19. Diffuse Noxious Inhibitory Controls [Title/Abstract]
9. Cold pain tolerance [Title/Abstract] 20. Temporal summation of pain [Title/Abstract]
10. Pressure pain sensitivity[Title/Abstract] 21. Windup [Title/Abstract]








29. 22 AND 28
Persistent Postsurgical Pain
30. Persistent pain after surgery [Title/Abstract]
31. Chronic postsurgical pain [Title/Abstract]
32. Surgery [MeSH Terms] [Emtree Term]
33. Persistent pain after operation [Title/Abstract]
34. Chronic pain after operation [Title/Abstract]
35. Persistent postsurgical pain [Title/Abstract]
36. Chronic pain after surgery[Title/Abstract]
37. OR/30-36
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Chronic pain following surgery, persistent postsurgical pain, is an important highly prevalent 
condition contributing to significant symptom burden and lower quality of life. Persistent 
postsurgical pain is relatively refractory to treatment hence generating a high need for preventive 
strategies and treatments. Therefore, the identification of patients at risk of developing persistent 
pain is an area of active ongoing research. Recently it was demonstrated that peri-operative 
disruptions in central pain processing may be able to predict persistent postsurgical pain at 
long term follow-up in breast cancer patients. The aim of the current report is to present a 
short protocol to obtain pain thresholds to different stimuli at multiple sites and a measure of 
endogenous analgesia in breast cancer patients. We have used this method successfully in a 
clinical context and detail some representative results from a clinical study.




Chronic pain following surgery, persistent postsurgical pain, is an important condition 
contributing to significant symptom burden and lower quality of life.1 Persistent post-surgical 
pain remains poorly understood, but is broadly recognized as pain lasting more than 3 months 
after surgery.2 The condition is common, with estimates of its prevalence ranging from 10% to 
50% of all postsurgical patients.3 High-risk procedures include breast surgery4, thoracotomy,5 
limb amputation,6 and hernia repair.7 Persistent postsurgical pain is relatively refractory to 
treatment and thus has generated interest in potential preventive strategies and treatments. A 
better understanding of predicting and characterizing persistent postoperative pain would help 
identify the subset of patients who are likely to require additional treatment to optimize their peri-
operative pain management.
Recently it was shown that abnormal changes in pain thresholds in response to surgery may 
be of predictive value for long-term persistent pain development in the context of surgery 
for breast cancer.8 Others have stressed the importance of the conditioned pain modulation 
(CPM) effect in predicting persistent postoperative pain, for example with regards to persistent 
pain after thoracotomy.5 CPM is the behavioral correlate of diffuse noxious inhibitory control, 
a physiological phenomenon where input from peripheral c-fibers results in diffuse inhibition 
from the brainstem of all incoming stimuli mediated by c-fiber from heterotopic fields.9 The CPM 
effect is measured by comparing thresholds to a noxious stimulus, which are measured before 
and after the application of a second different stimulus, which is referred to as the conditioning 
stimulus.10
Current standardized quantitative sensory testing (QST) protocols, such as the German Research 
Network on Neuropathic Pain protocol are quite extensive and may not be suitable to perform 
in surgical patients.11 The aim of the current publication is to detail a short and standardized 
protocol to obtain both pain thresholds and a CPM effect measurement in breast cancer surgery 
patients. This protocol is derived from a collaborative protocol between our university and the 




This protocol has been approved in the context of a previous randomized controlled trial8 by the 
human research ethics committee region Arnhem-Nijmegen, the Netherlands (nr. 2004/239).
1. Preparation for Testing
 1. Informed consent:
 1.  Review the informed consent form together with the patient.
 2.  Answer any questions that patient may have regarding the study.
 3.  Obtain written informed consent by having the patient sign the informed consent form and 
signing it yourself.
 2. Testing environment:
 1.  Perform all the measurements in the protocol in a stimulus poor and temperature 
stable environment (~21 °C, no music, no uncovered windows, phones switched off). 
NOTE: The clothing of the experimenter needs to be as neutral as possible, i.e. wear 
a lab coat, be ‘naked below the elbows,’ wear no jewelry, and wear no perfume. It is 
well known that experimenter related factors may have influence on the outcome of the 
measurements. Some of these factors are not completely standardizable (e.g. sex), but 
one should keep this in mind when preparing the performance of the measurements.
 2.  During measurements, ensure that the patient and the researcher are the only people in 
the room, ask others to leave.
 3.  Attach a ‘do not disturb’ sign to the door to avoid being disturbed during the measurements.
 4.  Perform all testing with the patient in the supine position on the bed, except for the CPM 
test, which is performed with the patient in sitting position.
 3. Sites of testing:
 1.  Mark the following sites for threshold testing using a surgical skin marker: 
area under the greater tubercle on bilateral shoulders (C5 dermatome, pressure and 
electric thresholds), the bilateral thenar (C6 dermatome, pressure), bilateral iliac crests (L1 
dermatome, pressure and electric), bilateral in the mid axillary line at nipple height or 7 cm 
from the surgical incision in case of breast cancer surgery (T4 dermatome, pressure and 
electric thresholds).
 2.  Mark the CPM testing side using a surgical skin marker: 15 cm above the patella on the 
non-dominant body site (L3 dermatome, pressure).
 3.  Mark a test run site using a surgical skin marker, for example, 15 cm above the patella on 
the dominant body side.
 4. Electrical stimulation configuration:
 1.  Apply two self-adhesive skin electrodes on each side of the marked spot on each electrical 
stimulation test site. Place the electrodes with their outer diameter such that they are just 
touching each other at the marked spot.
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 2.  Set the QST stimulator to deliver tetanic stimulation (100 Hz, 0.2 ms square waves) – Figure 1. 
Set the ramping rate to 1 mA/s. Set the initial current to 0 mA, the maximum current is 
automatically set to 50 mA for safety purposes.
Figure 1. Screenshot of the software interface and the appropriate settings to be used for electrical QST 
measurement. 
2. Electrical Pain Thresholds
 1. Delivery of electricity:
 1.  Use the QST stimulator. Connect the self-adhesive electrodes to the stimulator using the 
connection leads.
 2. Measurement of visual analogue scale (VAS):
 1.  Use the VAS slider connected to the QST stimulator to obtain VAS scores. The VAS slider 
consists of a box with a mobile lever on a horizontal bar that represents the VAS. Hand the 
slider to the patient.
 2.  Explain the patient how to use the slider: “The control unit has a slider. This slider can 




 3. Test run:
 1.  Explain the procedure for the electrical detection threshold (EDT) to the patient: “We will 
conduct a test run to get you familiarized with the measurement. The stimulation will start 
when you press the button, will gradually increase, and will stop immediately upon letting 
go of the button. Please press the button when I tell you to do so and let go when you feel 
anything.” NOTE: All instructions are read from a manual to aid in standardization.
 2.  Perform a single test run on the test run site to demonstrate the procedure. Record the 
result on the measurement sheet — Figure 2. Make sure the patient cannot read the 
values of the measurements during the execution of the tests.
 3.  Ask the patient to indicate how he/she experienced the stimulus using the VAS slider and 
note the result.
 4.  Explain the procedure for the electrical pain threshold (EPT) to the patient: “We will conduct 
a test run to get you familiarized with the measurement. This test is aimed at determining 
your pain perception in response to electrical stimulation. The stimulation will start when 
you press the button, will gradually increase, and will stop immediately upon letting go of 
the button. Please press the button when I tell you to do so and let go when the stimulation 
becomes painful.”
 5.  Perform a single test run on the testing site to demonstrate the procedure. Record the 
result on the measurement sheet.
 6.  Ask the patient to indicate how he/she experienced the stimulus using the VAS slider and 
note the result.
 4. Measurement:
 1.  Explain the procedure for EDT again to the patient, using wording from 2.3.1.
 2.  Measure the EDT at the different study sites (first C5, then T4, then L1). Perform EDT 
measurement three times at each measurement site, allow at least 15 seconds in between 
measurements to avoid windup effects.
 3.  Ask the patient to rate the associated pain on VAS after the last EDT measurement at each 
site. Note electrical values and VAS scores on the measurement sheet. Make sure the 
patient cannot read the values of the measurements during the execution of the tests.
 4.  Explain the procedure to determine the EPT again using wording from 2.3.4.
 5.  Measure the EPT at the different study sites (first C5, then T4, then L1). Perform EPT 
measurement three times at each measurement site, allow at least 15 seconds in between 
measurements to avoid windup effects.
 6.  Ask the patient to rate the associated pain on VAS after the last EPT measurement at each 
site.
 7.  Note electrical values and VAS scores on the measurement sheet. Make sure the patient 
cannot read the values of the measurements during the execution of the tests.
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Figure 2. Scoring sheet. N: Newton; mA: milliAmpere; VAS: visual analogue scale; EDT: Electrical detection 
threshold; EPT: Electrical pain threshold; CPM, Conditioned pain modulation; PA: Pressure algometry; IWB: 
Ice water bucket test.
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3. Pressure Pain Thresholds
 1. Delivery of pressure:
 1.  Deliver pressure with the pressure algometer with a 1.0 cm2 probe under a 90° angle. Use 
a ramping rate of ~5 N/s by manually adjusting the applied pressure and the pressure 
on the display. Start at 0 N and apply up to a maximum of 200 N for safety purposes. 
NOTE: Be careful not to let the device skid on the skin. To prevent skidding of the algometer 
it is important to place the probe perpendicular to the skin and to support the algometer 
with both hands while slowly increasing the pressure. The researcher should stand firmly 
to provide a controlled increase in pressure.
 2. Test run:
 1.  Explain the procedure to the patient: “We will conduct a test run to get you familiarized with 
the measurement. This measurement is aimed at determining your perception of pressure 
pain in muscle. I will put a pressure measurement device on your muscle and will gradually 
increase the pressure. Please notify me when the pressure feeling becomes throbbing, 
burning, or painful by saying ‘now.’”
 2.  Perform a single test run on the test site. Make sure the patient cannot read the values of 
the measurements during the execution of the tests. Record the result on the measurement 
sheet.
 3. Measurement:
 1.  Repeat the instructions for the patient using wording from 3.2.1.
 2.  Apply pressure to the different study sites (first C5, then C6, then T4, then L1). Perform 
pressure pain threshold (PPT) measurement two times at each measurement site, allow at 
least 15 seconds in between measurements to avoid windup effects.
 3.  Ask the patient to rate the associated pain on VAS after the last PPT measurement at each 
site.
 4.  Note pressure values and VAS scores on the measurement sheet.
4. Conditioned Pain Modulation Paradigm
 1. Preconditioning test stimulus:
 1.  Repeat 3.1.1. but use PPT as test stimulus. Repeat the instructions for the patient using 
wording from 3.2.1.
 2.  Measure pre-conditioning PPT at the CPM testing site (m. rectus femoris (L3) on the non-
dominant side, 15 cm above the patella). Ask the patient to rate the associated pain on the 
VAS slider. Note the value at which the pressure become painful and the associated pain 
score.
 3.  Explain the ice water procedure to the patient: “This is a test to gain information on the way 
your body processes different pain signals at the same time. I will ask you to submerse your 
hand into the ice water in the bucket. Place your hand in the water up to the wrist and with the 
fingers spread. Please hold your hand in the ice water until you can no longer tolerate it.”
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 4.  Tell the patient to remove their hand from the water after 3 minutes of immersion or sooner 
if the pain becomes intolerable. “Every 10 seconds, I will ask you to rate the pain on a 0 to 
10 scale, in which 0 represents no pain and 10 unbearable pain. After you take your hand 
out of the ice water we will measure the pressure pain threshold on your leg again, similar 
to how we did that before.”
 2. Conditioning stimulus:
 1.  Use the cold pressor task as conditioning stimulus. Measure the water temperature using a 
temperature probe and note the temperature (target temperature between 1 °C and 4 °C).
 2.  Ask patient to immerse dominant hand in ice-chilled water. Ask the patient to rate the 
pain throughout the cold pressure task every 10 seconds on VAS and note the result. 
Note the completed immersion time on the measurement sheet (maximum duration is 180 
seconds, on average 56 ± 55 s).8
 3. Determine test stimulus post-conditioning:
 1.  Measure PPT on the CPM test site after the conditioning stimulus. Ask the patient to rate 
the associated pain on VAS and note PPT and VAS score on sheet.
5. Calculations
 1. EPTs:
 1.  Calculate the mean value for each testing location of the EDTs and EPTs.
 2. PPTs:
 1.  Calculate the mean value for each testing location of the PPTs.
 3. CPM:
 1.  Determine the CPM effect by calculating the relative change (in %) in the 
PPT at the CPM test location before and after the conditioning stimulus.10 
CPM = ([PPTpost – PPTpre] / PPTpre) * 100 
REPRESENTATIVE RESULTS
In a previously published clinical trial in women (N = 94) undergoing surgery for breast cancer, 
we measured electrical and pressure pain thresholds as well as CPM using the protocol 
described in this report.8 We performed the testing paradigm pre-operatively and at various time 
points throughout the year following surgery. We found that women who developed persistent 
postsurgical pain 12 months after breast cancer surgery, defined as a VAS of >30 mm, exhibit 
lower pressure pain thresholds both early and late after surgery. Figure 3 details the changes in 
pressure pain thresholds both early (Figure 3A) and late (Figure 3B) after surgery. For simplicity’s 
sake, the pressure pain thresholds at different measurement sites are summated and expressed 
as change vs. baseline. Using logistic regression, we found that for every 10% lower thresholds 
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5 days after surgery, patients were 50% more likely to exhibit chronic pain at 12 months after 
surgery (confidence interval 10–100% more likely, p = 0.01).
Figure 3. Change in pressure pain thresholds in the year following breast cancer surgery. 
Panels A and B show the mean ± SE at the early and late postoperative time points, respectively. Time 
points are labeled in relationship to surgery, baseline assessment was ~1 week prior to surgery. Analysis 
was by mixed models analysis using factors ‘Time’ and ‘Persistent Pain’ with Bonferroni corrected post 
hoc comparison of individual time points. *Different vs. patients without persistent pain at 12 months 
postoperatively (α-level 0.05), specifically: p = 0.02 at day 5; p <0.01 at day 15; p <0.01 at 30 days; p = 
0.02 at 3 months; p ≤0.01 at 6 months and; p = 0.03 at 12 months. This figure has been modified from van 
Helmond et al.8
DISCUSSION
Our method of quantifying pressure pain thresholds, electrical pain thresholds, and CPM can 
be successfully applied in a clinical context given its short duration (~20 minutes). We have 
previously shown that pressure pain values obtained early after surgery may be of value in 
predicting persistent pain at long term follow-up in the context of breast cancer surgery.8 While 
electrical pain thresholds and CPM were not predictive of persistent pain in our study, others have 
shown that these measures may be of value with regards to other procedures.5,13 A limitation of 
using electrical pain thresholds is that it may represent an unnatural stimulus. However, the 
fact that it bypasses local modulation and that it offers very precise control over intensity and 
timing, improving repeatability, led us to include it in the current protocol.14 Alternative stimulus 
modalities, such as heat, could potentially be used to replace the electrical stimulus in the 
present protocol.
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We hope that detailing a circumscribed, yet valuable, quantitative sensory testing paradigm 
will lead to wider application of these measures in the context of the study of persistent pain 
after breast cancer. Once more perioperative quantitative sensory testing data become available 
it may be possible to identify subpopulations of patients that are at high risk of developing 
persistent postsurgical pain, and to tailor periprocedural treatments to minimize the risk of 
eventually developing persistent pain.
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Bed N/A N/A Any type of hospital bed or medical exam table
Desk N/A N/A Any type of commercially available desk
Office chair N/A N/A Any type of commercially available office chair





Pressure algometer with a 1.0 cm2 circular tip to 
deliver pressure to perform pressure pain threshold 
measurements
Desktop computer N/A N/A
Any type of commercially available Windows 
computer to run QST-IV Stimulus Manager software 
on to control the QST-IV stimulator
QST-IV Stimulus 
Manager
Embedded Control BV, 
Ruurlo, the Netherlands
N/A




Embedded Control BV, 
Ruurlo, the Netherlands
N/A
Electrical quantitative sensory testing device with 
a patient operated switch. Device used to deliver 
electrical current to perform the electrical threshold 
measurements
VAS Slider
Embedded Control BV, 
Ruurlo, the Netherlands
N/A
The VAS slider consists of a box with a mobile lever 
on a horizontal bar that represents the VAS and is 
connected to the QST-IV.
Kendall H34SG 50 x 
45 mm
Covidien, Mansfield, USA N/A
Self-adhesive skin electrodes to apply to the 
measurement points on the skin to deliver electrical 
stimualtion
Crushed Ice N/A N/A
Ice generated by ice machine to cool water 
sufficiently for the cold pressor test
Bucket N/A N/A Any type of commercially available 10 L bucket
Surgical skin marker Covidien, Mansfield, USA N/A
Any type of commercially available surgical skin 
marker
Stopwatch N/A N/A Any type of commercially available stopwatch
Measurement form N/A N/A Score form provided in the manuscript
Pencil N/A N/A Any type of commercially available pencil
Thermometer N/A N/A
Thermometer to measure water temperature of ice 
water
Ruler N/A N/A Any type of commercially available ruler
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Background: Persistent pain is a challenging clinical problem after breast cancer treatment. After 
surgery, inflammatory pain and nociceptive input from nerve injury induce central sensitization 
which may play a role in the genesis of persistent pain. Using quantitative sensory testing, we 
tested the hypothesis that adding COX-2 inhibition to standard treatment reduces hyperalgesia 
after breast cancer surgery. A secondary hypothesis was that patients developing persistent 
pain would exhibit more postoperative hyperalgesia.
Methods: 138 women scheduled for lumpectomy/mastectomy under general anesthesia with 
paravertebral block were randomized to COX-2 inhibition (2x40mg parecoxib on day of surgery, 
thereafter 2x200mg celecoxib/day until day five) or placebo. Preoperatively and 1, 5, 15 days 
and 1, 3, 6, 12 months postoperatively, we determined electric and pressure pain tolerance 
thresholds in dermatomes C6/T4/L1 and a 100-mm VAS score for pain. We calculated the sum 
of pain tolerance thresholds and analyzed change in these versus preoperatively using mixed 
models analysis with factor medication. To assess hyperalgesia in persistent pain patients we 
performed an additional analysis on patients reporting VAS>30 at 12 months.
Results: 48 COX-2 inhibition and 46 placebo patients were analyzed in a modified intention to 
treat analysis. Contrary to our primary hypothesis, change in the sum of tolerance thresholds in 
the COX-2 inhibition group was not different versus placebo. COX-2 inhibition had an effect on 
pain on movement at postoperative day 5 (p<0.01). Consistent with our secondary hypothesis, 
change in sum of pressure pain tolerance thresholds in 11 patients that developed persistent 
pain was negative versus patients without pain (p<0.01) from day 5 to 1 year postoperatively. 
Conclusions: Perioperative COX-2 inhibition has limited value in preventing sensitization and 
persistent pain after breast cancer surgery. Central sensitization may play a role in the genesis 
of persistent postsurgical pain. 




Persistent pain after surgery is a significant clinical problem which affects 10 to 50 percent of 
patients.1 Chronic pain treatments are effective in reducing pain in only about 30 percent of 
patients with such persistent pain.2 In breast cancer surgery similar outcomes are reported, with 
around 40 percent of patients suffering from persistent pain one year after surgery.3,4 These results 
are not surprising in view of the complexity of persistent pain and current empirical symptom-
based pain management approaches. Further improvement in persistent and chronic pain 
management will likely depend on the development of more mechanism-based approaches.5, 6 
A key insight from fundamental pain research is that ongoing nociceptive input alters subsequent 
sensory processing by the nervous system.7 Surgical nociception results in postoperative 
hyperalgesia via pronociceptive changes in central nervous system processing. Such ‘central 
sensitization’ occurs via two mechanisms, namely damage to tissues and to nerves, with the 
former acting more via humoral biochemical products of tissue inflammation, and the latter more 
via neuronal mechanisms.7 Postoperative central sensitization and hyperalgesia not only lead to 
increased acute pain, they have also been linked to subsequent development of chronic pain.8-13 
Preventing postoperative central sensitization may therefore provide an attractive mechanism 
based approach to prevent persistent pain development, e.g. by blocking nociceptive input or 
direct antihyperalgesic therapy.14-18
Regional anesthesia is currently the best therapy to block surgical nociceptive input and may 
protect partially against persistent pain development after surgery.19-21 However, even with 
paravertebral block around twenty-two percent of women undergoing breast cancer surgery 
suffer from persistent pain six months after surgery.22, 23 To further improve management of 
surgical pain it would be useful to understand the effect of adding inhibition of the inflammatory 
component of sensitization, e.g. by providing perioperative cyclooxygenase-2 (COX-2) inhibition 
in addition to blockade of neuronal nociceptive input.24-26 COX-2 inhibitors interfere with 
prostaglandin production and may counteract central sensitization development by inhibiting 
peripheral sensitization and reducing nociceptive input.27 Additionally, COX-2 inhibitors may 
prevent central sensitization by a central mechanism.24, 27 
The primary aim of this study was to assess the value of perioperatively inhibiting the 
inflammatory component of sensitization added to blockade of neuronal nociceptive input on 
central sensitization after surgery. A secondary aim was to assess the relationship between 
hyperalgesia and persistent pain development at 12 months postoperatively. We studied these 
aims in a randomized prospective controlled trial in women undergoing breast cancer surgery 




1.  Adding COX-2 inhibition to standard maximal antinociceptive treatment (paravertabral 
blockade) perioperatively would result in less widespread hyperalgesia as a sign of central 
sensitization – and therefore less persistent pain – following surgery compared to a placebo-
supplemented group.
2.  Patients who complained of persistent pain 12 months postoperatively would exhibit more 
widespread hyperalgesia following surgery than patients not complaining of persisting pain.   
MATERIALS AND METHODS
We conducted a prospective, randomized, double blind, placebo-controlled, clinical trial at the 
Bernhoven Hospital in Uden, the Netherlands, approved by the Ethical Committee on March 16th 
2005 (nr: 2004/239, CMO region Arnhem-Nijmegen, Nijmegen, The Netherlands). All participants 
provided written informed consent; the trial was registered with the Netherlands Trial Register 
(NTR1793). Trial registration was not complete when subject recruitment had begun. However, 
this was rectified and our trial was registered on May 3rd 2009. The authors confirm that all 
ongoing and related trials for this drug/intervention are registered. The protocol for this trial and 
supporting CONSORT checklist are available as supporting information; see S1 Checklist and 
S1 Protocol.
Patients
We included women scheduled for breast cancer surgery. Two dedicated breast surgeons 
performed all surgeries. Surgery was by lumpectomy, total simple mastectomy or modified 
radical mastectomy. Exclusion criteria were: previous breast surgery, planned immediate breast 
reconstruction, chronic pain syndromes (e.g. fibromyalgia, osteoarthritis), regular analgesic 
medication for 2 weeks preceding surgery, pre-existing central nervous system pathology (e.g. 
stroke, dementia), conditions predisposing to neuropathy (e.g. diabetes mellitus, alcohol abuse), 
inability to comply with testing procedures or to give informed consent, presence of contra-
indications to COX-2 therapy (including untreated hypertension, active or recent gastrointestinal 
ulceration) and contraindications to paravertebral blockade.
Randomization and treatment
After obtaining informed consent during an outpatient anesthesia visit, eligible patients were 
randomized in a one-to-one ratio to receive perioperative COX-2 inhibition or placebo. A 
pseudo-random code was computer generated for the randomization blocks that had a size 
of six. Stratified random sampling ensured equal distribution of axillary lymph node dissections 
over groups. The hospital pharmacy held the randomization scheme for the trial and supplied 
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parecoxib and celecoxib (active treatment) or placebo in blinded packages. Parecoxib is 
currently not FDA approved, but is widely available worldwide, including in the European Union 
as the only injectable COX-2 specific inhibitor. The morning of surgery, patients received oral 
midazolam premedication (7.5 mg). In the operating theatre, COX-2 inhibition group patients 
received parecoxib 40 mg i.v. 30 minutes before surgery start. This injection was repeated 6 
hours later. The postoperative morning, patients started celecoxib 200 mg, continued to the 
morning of day five postoperatively. The placebo group received placebo injections and tablets 
according to the same regime. Medication was blinded, neither observers nor persons involved 
in patient management were aware of patient assignment.
Anesthesia and analgesia
Paravertebral blockade was by standard technique (20 ml ropivacaine 0.75%). Before surgery, 
local anaesthetic blockade was tested using pin-prick. Unsuccessful block, as defined by 
no hypoalgesia to pinprick, led to patient exclusion. Patients received standardized general 
anaesthesia,28 (propofol 2-3 mg/kg, fentanyl 3 µg/kg, rocuronium 0.5 mg/kg, air/oxygen 
[40%], sevoflurane) to achieve haemodynamic values within 20% of preoperative baseline. For 
procedures longer than 45 minutes, further fentanyl supplementation (1 µg/kg) was permitted 
at 45 minutes and at further 45-minute intervals. No further myorelaxants were given and no 
antagonisation was performed. In the recovery room, initial analgesia consisted of piritramide 
as soon as patients complained of pain, titrated to VAS≤3 by the recovery room nurse using 3 
mg intravenous increments. Thereafter, standard postoperative analgesia consisted of a fixed 
acetaminophen scheme (4 X 1g /day) together with on-demand tramadol (drops, maximum 300 
mg/day) up to day 5 postoperatively. 
Measurement protocols
Trained research personnel performed all testing in a standardized fashion in a quiet room. 
All subjects underwent familiarization training with sensory testing before the study. Pain was 
assessed via 100 mm visual analogue scores at rest (lying quietly in bed) and on movement 
(immediately after sitting up on bed). For all postoperative pain scores, the patient was explicitly 
asked to report pain associated with surgery at that moment. At several time points patients 
were asked to complete a quality of life questionnaire assessing surgery-related symptoms and 
functional impairment. 
Postoperative changes in pain sensitivity (hyperalgesia) were quantified using electric and pressure 
pain tolerance thresholds. Electricity stimulates mainly cutaneous nerve endings,29 bypassing 
nociceptors; pressure reveals deep tissue sensitivity (e.g. muscle), with only minimal cutaneous 
contributions.30 Thus electric pain tolerance thresholds mainly reflect cutaneous sensitivity and 
pressure pain tolerance thresholds mainly reflect deep tissue sensitivity. Thresholds were measured 
close to the affected breast and distant from the site of surgery to obtain measures of secondary 
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(peri-incisional) and spreading (or generalizing) hyperalgesia, respectively. Pain modulation was 
assessed preoperatively via conditioned pain modulation (CPM) paradigm.31 At no time were 
patients or treating personnel aware of results of pain processing tests. 
Baseline demographic data, electric pain tolerance thresholds, pressure pain tolerance 
thresholds and CPM were collected the preoperative afternoon. Pain scores, electric pain 
tolerance thresholds and pressure pain tolerance thresholds were collected 1, 5 and 15 days 
after surgery and at 1, 3, 6 and 12 months after surgery.  
Electric and pressure pain tolerance thresholds 
Electric pain tolerance threshold testing was performed using an electric stimulation device (QST-
3; JNI, Aalborg, Denmark), delivering electrical tetanic stimulation (100 Hz, 0.2-ms square waves, 
0.1mA/s ramping rate) via self-adhesive skin electrodes 3 cm apart. A trained research assistant 
operated the device and documented the value at which stimulation became intolerable and was 
discontinued. Pain tolerance thresholds were determined three times and the mean value was 
used. Pressure pain tolerance thresholds were assessed using a pressure algometer (Somedic 
Sales AB, Horby, Sweden) with a 1.0 cm2 probe and a ramping rate of 50 kPa/s until the patient 
did not accept a higher stimulus intensity.28 The electric pain tolerance thresholds were measured 
at each of the following sites on both the affected body side and the contralateral side:  Radial 
upper arm (C6 dermatome), mid-axillary line (T4 dermatome, 5-10 cm from incision, affected 
side) and iliac crest (L1 dermatome). The pressure pain tolerance thresholds were measured 
bilaterally on the index finger (C6 dermatome), iliac crest (L1 dermatome) and sternum in the 
midline (T4 dermatome). To avoid mass significance and as a measure of central sensitization 
the sum of all the thresholds (SOT) across dermatomes was calculated for the electric thresholds 
and for the pressure thresholds.14 Postoperative changes in SOTs were expressed as percentage 
changes compared to preoperative baseline. 
Conditioned pain modulation (CPM) paradigm 
The condition pain modulation paradigm tests the ability to generate descending inhibitory 
modulation.31 An electric pain threshold (test stimulus) was determined before and after a cold 
pressor task (conditioning stimulus), and the CPM effect was determined as the relative change 
(%) in electric pain threshold. For the cold pressor task the dominant hand was immersed in ice-
chilled water (1.0°C ±0.3°C) stirred by pump. The patient was told to remove the hand from the 
water after two minutes of immersion – or sooner if the pain was considered intolerable – and 
immersion time was noted. Immediately after the cold pressor task, the subjects rated the pain 
experienced during the test by VAS for quality control purposes. Electric pain thresholds were 
obtained in the L1 dermatome immediately before and after ice-water immersion.




At baseline and 1, 3, 6, and 12 months post surgery patients filled out a quality of life questionnaire 
(Dutch version of the European Organization for Research and Treatment of Cancer Quality of 
Life Questionnaire-C30). The EORTC QLQ-C30 is internationally validated for evaluating quality 
of life in daily living and symptoms and side effects related to different treatment modalities.32 
The individual functional, symptom and quality of life (QOL) scales were summated to create 
general sum scores.33 We calculated symptom, functioning and QOL sum scores from the 
EORTC questionnaires. 
Outcome measures
The primary study outcomes are change in electric and pressure SOT after surgery vs. baseline 
values. Secondary outcomes are VAS pain and EORTC symptom, functional and QOL sum 
scores. 
Power-analysis
Based on data from previous postoperative quantitative sensory testing studies by our group 
we can expect electric pain tolerance thresholds in thoracic dermatomes five days after surgery 
to be 8.1 mA (SD= 4.5 mA).28, 34 Sample size calculation based on these data for Type 1 error 
(alpha) of 0.05 and power (1-beta) of 80% predicts ability to detect a clinically relevant change 
in pain tolerance thresholds of one third with a sample size per group of 45 patients. Assuming 
a drop-out rate of 20-25%, a sample size of n=55 per group should suffice to detect clinically 
relevant reductions of one-third in the pain tolerance threshold (vs. the other group) at 5 days 
postoperatively.
Data and statistical analysis
Data were analyzed with Statistica (version 12.0, Statsoft, Tulsa, OK, USA), p<0.05 was 
considered significant. Results are expressed as mean ± 95% confidence interval. Postoperative 
sums of thresholds were expressed as percentage change compared to preoperative baseline. 
Chi-squared tests and t-tests were used to assess differences between the treatment groups 
regarding axillary lymph node dissection, type of surgery, duration of surgery, surgical 
complications, size of specimen removed, baseline electric SOT, baseline pressure SOT, baseline 
CPM, baseline QOL-score, baseline functioning score and baseline symptom score. 
Our main analysis was aimed at testing our primary hypothesis that perioperative COX-2 inhibition 
would result in less hyperalgesia as a sign of central sensitization following surgery compared 
to a placebo-supplemented group. We performed mixed model analyses on change in electric 
and pressure SOT, and on secondary outcomes VAS scores and EORTC sum scores with fixed 
factors medication (COX-2 inhibition vs. placebo) and time, and subjects were included as random 
factor. Preoperative CPM is reported in the literature as a predictor for persistent postsurgical 
CHAPTER 5
104
pain development and was included as covariate.35 We performed a (modified) intention to 
treat analysis, which included all patients that received at least one dose of study drug (COX-2 
inhibition or placebo).36-39 Post-hoc tests with Bonferroni correction were used to identify significant 
differences between medication groups or time levels when a main or interaction effect for the 
factors was found. A two-sided p-value <0.05 was considered significant for all tests.
To test our secondary hypothesis that patients developing persistent pain 12 months 
postoperatively would exhibit more hyperalgesia following surgery than patients not complaining 
of persisting pain two groups were formed post hoc: patients with persistent pain 12 months 
postoperatively (answering “yes” to the question: ”do you have persistent pain due to your 
surgery”, plus reporting pain at rest or on movement of >30 mm on VAS) or those without 
persistent pain. The chosen cutoff score  >30 mm VAS is widely used in the pain literature,40,41 
corresponds to moderate or severe pain,42 and a 30 mm VAS difference is a relevant treatment 
difference.43,44 We performed additional mixed model analyses on SOTs, pain scores and QOL 
scores to assess differences between these two groups. Post-hoc tests with Bonferroni correction 
were used to identify significant differences between patients with and without persistent pain or 
time levels when a main or interaction effect for the factors was found.
RESULTS
From October 2006 to December 2010 a total of 327 patients were screened for eligibility and 138 
patients were randomized (Fig 1). There was a relatively high exclusion rate due to treatment failure 
(unsuccessful paravertebral block) in 5 patients and failure of the hospital pharmacy to deliver 
study drugs to the operating room on time in 30 patients. 6 patients were excluded because they 
were found not to be suffering from malignant disease after pathological examination. 94 patients 
were analyzed in the modified intention to treat analyses. When we compared demographics of 
excluded patients for mastectomy rate (32 vs. 28%, chi-squared test p=0.59) and age (56 ± 14 
vs. 53 ± 10, unpaired t-test p=0.27) we found them to be comparable to the analyzed groups.
There were no differences in baseline and demographic data between the placebo and COX-2 
inhibition group (Table 1). Surgical complications occurred in 5 patients in the placebo group, 
consisting of hematomas that had to be drained in 3 patients, an abscess that had to be drained, 
and a nipple granuloma that had to be removed operatively. One patient in the COX-2 inhibition 
group developed an infected seroma that had to be drained. Because immediate reconstruction 
was an exclusion criterion, there was only one patient (in the COX-2 inhibition group) that underwent 
reconstruction by insertion of a tissue expander and subpectoral prosthesis implantation (495 
cc, Mentor©, Minneapolis, MN, USA) in the year following the initial breast cancer surgery. There 
were no harmful or unintended effects associated with COX-2 inhibition. 
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Figure 1. Study enrollment and randomization. 
Table 1. Demographic data of patients receiving COX-2 inhibition and placebo medication.
COX-2 inhibition (n=48) Placebo (n=46) P-value
Age in years 51 ± 9 55 ± 11 0.09
Body Mass Index in kg/m2 26 ± 5 25 ± 4 0.46
All mastectomies in % 25 30 0.56
Modified radical mastectomy in % 15 9 0.57
Axillary lymph node dissection in % 35 39 0.71
Duration of surgery in minutes 48 ± 25 44 ± 20 0.39
Size of specimen removed in cm3 435 ± 747 437 ± 695 0.99
Surgical complications in % 2 11 0.08
Chemotherapy in % 35 43 0.42
Radiotherapy in % 67 50 0.10
Electric SOT in mA 59 ± 29 58 ± 20 0.86
Pressure SOT in kPa 3167 ± 1397 2797 ± 1102 0.16
CPM in % 40 ± 43 29 ± 35 0.19
Functioning score 82 ± 14 86 ± 12 0.14
Symptom score 11 ± 12 9 ± 7 0.34
QOL score 70 ± 23 76 ± 18 0.23
Data are mean ± sd, continuous data were compared using unpaired t-tests, binomial data using chi-
squared tests. SOT, sum of thresholds, CPM, conditioned pain modulation, QOL, quality of life.
CHAPTER 5
106
PRIMARY HYPOTHESIS: HYPERALGESIA AND COX-2 INHIBITION 
Electric and pressure SOT 
Perioperative treatment with COX-2 inhibition was not associated with postoperative differences 
in tolerance to electric or pressure stimulation (Fig 2 and Table 2).
Figure 2. Effect of medication on electric and pressure SOT and VAS scores. 
Panels A + B show mean change ± 95% CI of SOT versus baseline, panels C + D show the mean ± 95 CI 
of VAS scores at the different time points. *Different vs. baseline (Bonferroni adjusted p<0.05); †Different vs. 
COX-2 inhibition (Bonferroni adjusted p<0.05). SOT, sum of thresholds, VAS, Visual Analogue Scale. 
VAS scores 
COX-2 inhibition did not affect VAS scores at rest but influenced VAS scores on movement (Time 
x Medication: p=0.02) – Fig 2 and Table 2. Post-hoc testing revealed that COX-2 inhibition led to 
lower postoperative VAS score on movement only on postoperative day 5.
















































































































































   


































































































































































































































































































   










































































































































































































































   


































































































































































































   




































































































































































































































   







































































































































   

















































































































































































Covariate preoperative CPM significantly affected electric SOT (p=0.04), and showed a trend 
towards significance on pressure SOT (p=0.06) – Table 2. Impaired preoperative CPM was 
related to more negative postoperative change in sensitivity. Of note, preoperative CPM did not 
influence postoperative VAS scores at rest or on movement.
EORTC sum scores 
EORTC functioning, symptom and QOL score were comparable between treatment groups   (Fig 
3 and Table 2). 
Figure 3. Effects of medication on EORTC function, symptom and QOL sum scores. 
Panels A-C show the mean ± 95% CI at the different time points. No difference between treatment groups at 
any time (all p>0.05). QOL, quality of life. 
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SECONDARY HYPOTHESIS: PERSISTENT PAIN AND HYPERALGESIA
Persistent postsurgical pain 
Twelve months postoperatively 11 patients (13%) complained of persistent pain with VAS>30 
mm. Characteristics of patients who eventually would develop persistent pain and patients free 
of pain are displayed in Table 3. Patients who would eventually develop persistent pain had 
higher baseline pressure SOT and electric SOT.
Table 3. Baseline characteristics of patients who eventually developed persistent and patients without pain.
With/Without persistent postsurgical pain
With persistent pain 
(n=11)
Without persistent pain 
(n=83)
P-value
Age in years 53 ± 7 54 ± 10 0.79
Body mass index in kg/m2 27 ± 7 26 ± 4 0.37
All mastectomies in % 36 27 0.53
Modified radical mastectomy in % 27 8 0.17
Axillary lymph node dissection in % 54 36 0.23
Duration of surgery in minutes 46 ± 22 53 ± 27 0.34
Size of specimen removed in cm3 508 ± 872 459 ± 741 0.84
Surgical complications in % 9 6 0.70
Chemotherapy in %  45 39 0.66
Radiotherapy in % 64 60 0.82
Electric SOT in mA 81 ± 37 56 ± 22 <0.01
Pressure SOT in kPa 4114 ± 1416 2821 ± 1224 <0.01
CPM in % 28 ± 56 33 ± 33 0.65
Functioning score 78 ± 16 85 ± 13 0.12
Symptom score 14 ± 12 9 ± 9 0.20
QOL score 80 ± 13 87± 11 0.09
Data are mean ± sd, continuous data were compared using unpaired t-tests, binomial data using chi-
squared tests. SOT, sum of thresholds, QOL, quality of life, CPM, conditioned pain modulation.
Electric and pressure SOT 
Patients in the persistent postsurgical pain group did not exhibit postoperative hyperalgesia 
to electric stimulation, but were significantly more hyperalgesic postoperatively to pressure 
stimulation (Persistent pain: p<0.01) – Fig 4 and Table 2. Post-hoc analysis revealed that 
persistent pain patients were hyperalgesic to pressure stimulation versus patients not developing 
pain on day 5 and throughout the rest of the postoperative year.  
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Figure 4. Electric and pressure SOT and VAS scores in persistent pain patients versus women without pain. 
Panels A + B show mean change ± 95% CI of SOT versus baseline, panels C + D show the mean ± 95% 
CI of VAS scores at the different time points. *Different vs. baseline (Bonferroni adjusted p<0.05); † Different 
vs. No persistent pain (Bonferroni adjusted p<0.05). SOT, sum of thresholds, VAS, Visual Analogue Score.
VAS scores 
Persistent pain patients had significantly higher postoperative pain VAS scores at rest  (Persistent 
pain: p<0.01, Time x Persistent pain: p<0.01) and on movement (Persistent pain: p=<0.01, 
Time x Persistent pain: p<0.01) – Fig 4 and Table 2. These differences existed at all early and 
late postoperative timepoints, except for VAS at rest on day 5. Paravertebral blockade provided 
excellent postoperative pain relief in the patients not developing persistent postsurgical pain. 
Preoperative CPM 
Covariate preoperative CPM significantly affected electric SOT (p=0.03) and showed a trend 
towards significance on pressure SOT (p=0.07) – Table 2. Impaired preoperative CPM was 
related to more negative postoperative change in sensitivity. Preoperative CPM did not influence 
postoperative VAS scores at rest or on movement.
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EORTC sum scores 
Patients in the persistent postsurgical pain group reported lower functioning score (Persistent 
pain: p<0.01) and total QOL (Persistent pain: p<0.01), and higher symptom score (Persistent 
pain: p<0.01, Time x Persistent pain: p<0.01) – Fig 5 and Table 2. Lower functioning score 
was present at 3, 6 and 12 months postoperatively for persistent pain patients. Persistent pain 
was associated with higher symptom score and lower total QOL score at 1, 3, 6 and 12 months 
postoperatively.
Figure 5. EORTC function, symptom and QOL sum scores in persistent pain patients versus patients with 
no pain. 
Panels A-C show the mean ± 95 CI at the different time points. *Different vs. baseline (Bonferroni adjusted 




We assessed the value of inhibiting the inflammatory component of sensitization added to 
blockade of neuronal nociceptive input (paravertebral blockade) on central sensitization 
(expressed as widespread hyperalgesia) and persistent pain after surgery in women undergoing 
surgery for breast malignancy. Adding perioperative COX-2 inhibition to maximal anti-nociceptive 
therapy had no impact on change in electric or pressure pain tolerance thresholds as a measure 
of central sensitization after breast cancer surgery. COX-2 inhibition did lead to lower pain scores 
on movement at postoperative day 5, but had no effect on later time points and did not affect 
quality of life scores. Thus, our primary hypothesis was rejected.  
We found that patients developing persistent postsurgical pain were significantly more 
hyperalgesic to pressure both early after surgery (5 days) and throughout the rest of the year (15 
days to 12 months). Thus, our secondary hypothesis was confirmed. There was no difference 
in sensitivity to electric quantitative sensory testing. Patients with persisting pain 12 months 
postoperatively had more pain in the acute postoperative period (1, 5 and 15 days) and the rest 
of the year (1, 3 and 6 months). Total QOL and functioning scores were lower in persistent pain 
patients and symptom score was higher vs. patients not developing persisting pain. 
Our study describes the effects of perioperative COX-2 inhibition on postoperative sensitization of 
pain processing in a long-term prospective and longitudinal trial. Regarding persistent pain (but 
not hyperalgesia) after breast surgery some data are available on perioperative COX-2 inhibition. 
Romundstad et al.45 found no difference versus placebo of a single peri-operative dose of 40 
mg parecoxib on persistent pain one year after surgery in patients undergoing augmentation 
mammaplasty. Another trial reported no impact on pain six months postoperatively of ibuprofen 
400 mg before mastectomy plus four additional doses afterwards.46 
Surgical tissue damage is associated with prostanoid production.47 This release, involving 
COX-2 induction, occurs peripherally and in the central nervous system.24 Peripheral release 
of prostanoids (PGE-2, PGI-2) sensitizes peripheral nociceptors. Centrally synthesized PGE-2, 
by increased COX-2 expression, leads directly to central sensitization of the pain system. COX-
2 inhibitors interfere with both the peripheral and the central prostaglandin production.24,27,48,49 
Therefore, perioperative inhibition of COX-2 was expected to ameliorate central sensitization 
and to increase pain thresholds, by both inhibiting peripheral nociceptive input and by inhibiting 
direct central sensitization under influence of prostaglandins. We did not observe this expected 
difference, suggesting that perioperative COX-2 induction and inflammation subsequent 
to tissue damage may be of little importance in inducing postoperative central sensitization. 
Interestingly, a small recent trial with parecoxib failed to induce a difference in pressure pain 
tolerance thresholds in CRPS patients outside the surgical context.50 
HYPERALGESIA AND PERSISTENT PAIN AFTER BREAST CANCER SURGERY
115
5
The generalized pressure hyperalgesia detected in this study suggests that persistent central 
sensitization is an important process in persistent pain development after surgery. Other 
quantitative sensory testing studies have assessed pain processing in women with persistent 
pain at single time-points after breast cancer surgery. These studies confirm the widespread 
mechanical hyperalgesia we observed.51, 52 Others have demonstrated enhanced sensitivity to 
electrical and thermal stimulation,53, 54 further supporting the presence of central sensitization 
in persistent pain after breast cancer treatment. Recently, Andersen et al. found a relationship 
between sensory disturbances and pain one week after surgery for breast cancer.55 Hyperalgesia 
has also been reported 5 days after back surgery and early postoperative hyperalgesia has 
been linked to persistent pain development in smaller studies after abdominal surgery.56,57,58 
Hyperalgesia in the postoperative period is likely to be expressed as increased pain experience, 
which we found for both VAS at rest and on movement. A significant relationship between 
early postoperative pain and persistent pain has previously been reported for breast cancer 
surgery11 and other interventions including cholecystectomy,8,9,13 groin hernia repair and thoracic 
surgery.10,12 
We observed a relatively low incidence of persistent postsurgical pain following surgery 
(13%) compared to other less recent studies (25 to 60%).59 Maximal peri-operative blockade 
of neuronal nociceptive input (paravertebral blockade), but also identification and attention to 
sparing intercostobrachial and other nerves during lymph node dissection in the present study,22 
may explain the low incidence of persistent pain.
IMPLICATIONS
Our results indicate that the role of COX-2 and inflammation in the genesis of postoperative 
hyperalgesia may be less important than that of neuronally mediated nociceptive input. Adding 
perioperative COX-2 inhibition to maximal neuronal anti-nociceptive therapy (paravertebral 
blockade) appears of limited clinical value in preventing postoperative hyperalgesia or persistent 
pain. 
Despite all patients receiving maximal neuronal anti-nociceptive therapy in the form of 
paravertebral blockade, 13% of patients still developed persistent pain postoperatively. These 
patients showed widespread hyperalgesia to pressure in the acute postoperative period and the 
rest of the year and would seem to be relatively resistant to current therapeutic interventions. 
Future studies should further explore causes of developing early and persistent postoperative 
hyperalgesia, possibly an important process during persistent pain development. 
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Clinically, the fact that persistent pain patients showed more widespread hyperalgesia to pressure 
in the acute postoperative period means that peri-operative monitoring using quantitative 
sensory testing should be able to identify patients at risk of developing persistent postsurgical 
pain, possibly allowing for targeted antihyperalgesic treatment. 
There is an increasing interest in the potential of perioperative quantitative sensory testing to 
predict persistent postsurgical pain. A relationship between peri-operative quantitative sensory 
testing measures and persistent pain has thus far been shown in only a limited number of 
studies. These studies demonstrated an association between persistent postsurgical pain and 
preoperative measures of widespread pain sensitization, such as pressure pain thresholds.60-63 
However most of these studies were conducted in the context of orthopedic joint surgery and 
represent a very different patient population. In the orthopedic population patients have often 
suffered from ongoing pain and nociceptive input for a prolonged time preoperatively, which 
may have lead to sensitized central pain processing even before surgery. Conversely, patients 
undergoing surgery for breast cancer are highly unlikely to have suffered from significant pain 
preoperatively and are thus unlikely to express centrally sensitized pain processing preoperatively. 
Future studies should clarify which quantitative sensory measurement at which time point can 
best predict persistent pain in the breast cancer population.
 
Prediction and possible interventions targeting persistent pain after breast cancer surgery are 
especially relevant given the poorer function scores and QOL we found with persistent pain after 
breast cancer surgery. Furthermore, persistent pain after breast cancer surgery is increasing in 
prevalence due to increased survival after breast cancer.59  
METHODS AND LIMITATIONS
We chose quantitative sensory testing measures as the main outcome measures because we 
intended to conduct a study investigating relations between COX-2 inhibition, hyperalgesia 
development and persistent pain after surgery. Pressure quantitative sensory testing detects 
hyperalgesia of deep tissues such as muscle as a manifestation of central sensitization,30 and is 
considered a clinically robust and reliable measurement.64 Electric quantitative sensory testing 
stimulates peripheral cutaneous nerve endings bypassing peripheral nociceptors in skin and 
is sensitive to local and descending modulation.29 These characteristics may explain why we 
found differences in pressure tolerance thresholds – but not in electric tolerance thresholds – in 
persistent pain patients. 
We measured electric and pressure pain tolerance thresholds at multiple topographic sites. 
Others have advocated extensive multimodal quantitative sensory testing protocols.65 These 
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protocols permit quantification of several different aspects of hyperalgesia, without, however, 
achieving testing altered sensitivity at multiple sites, and are time-consuming. We chose our 
battery of tests for its suitability for implementation into clinical practice. This testing protocol 
generally lasts about 30 minutes and is well-accepted by patients with good reproducibility 
(within 20%).66
  
Two limitations pertain to this study. First, we were unable to include some patients in the modified 
intention to treat analysis due to treatment failure, and had to exclude some patients due to an 
incorrect initial diagnosis. However, we achieved the group size we calculated beforehand to 
deliver sufficient power to detect a 30% difference from baseline and the analyzed treatment 
groups were comparable for baseline characteristics. A second limitation was the small number 
of patients developing pain 12 months postoperatively. A larger study population and thus a 
larger group of pain patients might have provided more insight into the different characteristics 
of persistent pain patients vs. patients not suffering from pain, even though we were able to 
detect several significant differences between the groups that we analyzed. 
CONCLUSIONS
In conclusion, we found that adding perioperative COX-2 inhibition to current maximal anti-
nociceptive therapy (paravertebral blockade) has no significant impact on central sensitization, 
persistent pain and QOL in the year following breast cancer surgery. Patients who developed 
persistent pain after breast cancer surgery were significantly more hyperalgesic, had higher pain 
scores and lower QOL throughout the year following surgery. Sensitization early after surgery 
may play a role in the genesis of persistent pain after breast cancer surgery and perioperative 
monitoring using quantitative sensory testing may be able to identify patients at risk of developing 
persistent pain. 
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Breast surgery for cancer is associated with both tissue and nerve damage, and is frequently 
followed not only by acute, but also by chronic pain, causing significant medical and social 
morbidity. The nociception of surgery is now recognised to result in postoperative hyperalgesia 
via changes in central nervous system processing (central sensitisation). Such neuroplasticity is 
mediated both via humoral (tissue damage leading to inflammation) and neuronal (nerve damage 
leading to neuropathy) nociceptive inputs. Postoperative hyperalgesia will lead to increased pain, 
which – together with nerve damage – has recently been linked to subsequent pain chronification 
in a number of studies. Based on animal studies, it is now accepted that a major mechanism for 
such pain chronification is the persistence of (abnormal) central sensitisation.
The aim of this study is to investigate the interaction between extended perioperative COX-2 
inhibition (starting before surgery and continuing 5 days into the postoperative period) and 
extended locoregional block (paravertebral block) using local anaesthetics on central sensitisation 
after breast surgery. This should enable us to gain insight into the relative contributions of 
humoral (inflammatory) and neuronal (neuropathic) nociceptive inputs to acute postoperative 
hyperalgesia, persistence of central sensitisation and pain chronification after breast surgery. 
The defined primary study endpoint is the persistence and extent of central sensitisation one 
month after breast surgery as measured by quantitative sensory testing. The study will further 
investigate effects on clinical pain and other outcome measures, and determine their relationship 
to measures of central sensitisation.
2. Rationale for study
Pain is common after breast surgery for malignancy. Both acute and chronic pain significantly 
affect quality of life and are thus undesirable of themselves. Moreover, pain can potentially affect 
other long-term outcomes of cancer surgery in the form of increased recurrence coupled with 
decreased survival via concomitant effects on the immune system (Liebeskind 1991, Bar-Yosef 
et al 2001).
A key insight from fundamental pain research over the last decades has been the finding that 
nociceptive input alters subsequent sensory processing by the nervous system (Coderre et al 
1993). Initially, this neuroplasticity is excitatory (“central sensitisation” for the central nervous 
system), thus resulting in increased sensitivity to pain (“hyperalgesia”) (Woolf & Salter 2000). 
Hyperalgesia after surgery is the result of two separate mechanisms, namely damage to 
tissues and to nerves, with the former acting more via humoral (biochemical products of tissue 
inflammation), and the latter more via neuronal (via nerve damage and stimulation) mechanisms 
(Coderre et al 1991, Woolf & Salter 2000, Wieseler-Frank et al. 2004). The relative contribution of 
the two mechanisms has not been investigated to date. 
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Tissue damage due to surgery is associated with the production of prostanoids (Samad et al. 
2002). This release, involving induction of COX-2, occurs not only peripherally but also in the 
central nervous system (Samad et al. 2001). Peripherally, the production of prostanoids sensitises 
peripheral nociceptors. Centrally, sensitisation and the accompanying sickness syndrome (fever, 
lethargy, diffuse pain, anorexia, etc) are induced by interleukin-1 beta causing the upregulation 
of COX-2 resulting in elevated prostaglandin E2 levels in the cerebrospinal fluid. This central 
response to inflammation can be inhibited by preventing central prostanoid production via block 
of interleukin-converting enzyme or COX-2, but not COX-1 (Samad et al. 2001, Svensson & Yaksh 
2002). Furthermore, a synergistic action between central and peripheral COX-2 inhibition has 
been suggested and demonstrated in this context (Samad et al. 2001). The effectiveness of 
extended perioperative COX-2 blockade in affecting postoperative pain and functional outcomes 
has recently been demonstrated (Buvanendran et al 2003)
The fact that neuronally carried nociceptive input from surgery is associated with central 
sensitisation is well-known and described, as is the fact that local anaesthetic blockade is an 
effective means of blocking such input (Coderre et al 1993).
Acute hyperalgesia after surgery is clearly undesirable of itself, as it will increase the amount 
of pain felt for a given nociceptive input. More pain means more stress, thus increasing the 
metabolic demands made on the body, resulting in increases in a variety of complications 
(Rodgers et al 2000). Furthermore, increased pain will also increase the impact of the pain on 
the immune system, a clearly unwanted consequence (Bar-Yosef et al 2001). Finally, more pain 
usually means more demand for analgesics, which have their own list of side-effects, many of 
them again unwelcome (e.g. opioid side-effects).
However, the effects of postoperative hyperalgesia do not remain limited to the acute period. 
As already mentioned, chronic pain syndromes are now recognised to be much more common 
than initially thought after surgery (Perkins & Kehlet 2000, Macrae 2001). It is also generally 
accepted today that the mechanism of pain chronification involves persistent and abnormal 
excitatory neuroplasticity after nociception (Coderre et al 1993, Woolf & Salter 2000). The details 
of this process remain incompletely understood and studied, particularly in the postsurgical 
context. Two main somatic risk factors for pain chronification after surgery have been identified 
in the literature from clinical studies to date: nerve damage and prolonged/abnormal pain in the 
early postoperative period (Perkins & Kehlet 2000, Macrae 2001). Nerve damage of itself can 
cause early postoperative hyperalgesia, and persistent and abnormal hyperalgesia in the early 
postoperative period – the result of nerve as well as tissue damage – is likely to be expressed 
as prolonged/abnormal pain in this period. In the context of the identification of persistent 
excitatory neuroplasticity as a basal mechanism of pain chronification, this makes 
it likely that the prevention of early postoperative hyperalgesia (due to sensitisation 
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resulting from tissue and nerve damage) – and of its persistence – will play and 
important role in the subsequent prevention of pain chronification.
For improved therapeutic management of the acute and chronic pain accompanying breast 
surgery it will be useful to better understand the relative contributions of tissue and nerve 
damage to the causation of acute and chronic pain. Breast surgery can involve both damage 
to soft tissues (the breast, inflammation, humoral input) as well as nervous structures (axillary 
sampling, neuropathy, neuronal imput). Thus this type of surgery permits us to study the 
question of differential involvement of inflammatory and neuropathic processes in acute and 
chronic pain outcomes by 1) observing the effects of breast surgery with or without axillary 
surgery, and 2) by observing the effects of drugs specifically modulating inflammatory effects 
(COX-2 inhibitors) in addition to the effect of techniques specifically modulating neuropathic 
effects (local anaesthetics).
The aim of this study is to investigate the interaction between extended perioperative COX-2 
inhibition (starting before surgery and continuing 5 days into the postoperative period) and 
extended locoregional block (paravertebral block) using local anaesthetics on excitatory 
neuroplasticity after breast surgery. This should enable us to gain insight into the relative 
contributions of humoral (inflammatory) and neuronal (neuropathic) inputs to acute postoperative 
hyperalgesia, persistence of central sensitisation and pain chronification after breast surgery. 
The defined primary study endpoint is the persistence and extent of central sensitisation one 
month after breast surgery as measured by quantitative sensory testing. The study will further 
investigate effects on clinical pain and other outcome measures, and determine their relationship 
to measures of central sensitisation.
3. Background Information
One year after mastectomy, a recent survey quoted 43-56% of patients as suffering from chronic 
pain, with 26-45% reporting neuropathic problems in the arm and 26-66% describing phantom 
breast pain (Tasmuth et al. 1999). High incidences of pain complications are also described 
in other publications (e.g. Carpenter et al 1998, Wallace et al 1996, Gottrup et al 2000). Pain 
complications after mastectomy are a significant source of morbidity and are significantly related 
to reductions in the quality of life (Tasmuth et al. 1999). More severe acute pain after various types 
of surgery has been linked to the development of late, chronic pain complications (Tasmuth et 
al. 1999, Tasmuth et al. 1997, Katz et al. 1996, Kalso et al. 1992, Dworkin et al. 1992). Pain in 
the cancer context has also been linked to impaired immune function and thus poorer survival 
(Bar-Yosef S et al 2001, Liebeskind 1991). 
Quantitative sensory testing (QST) permits us to quantify nervous system input-response 
relationships in humans, allowing detection and quantification of neuroplasticity after nociception. 
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QST thus provides insight into nociceptive mechanisms, with the potential to provide the 
diagnostics necessary for mechanism-based approaches to perioperative nociception and 
pain management. In several studies, we have demonstrated that QST based upon electric 
transcutaneous stimulation is feasible for the demonstration of neuroplasticity in the perioperative 
clinical context (Wilder-Smith et al 1996, 1998, 2002, 2003).
Parecoxib is an injectable member of the new generation of highly selective COX-2 inhibitors. 
Parecoxib 20-40mg i.v. has been demonstrated to possess an analgesic efficacy at least equal to 
4 mg morphine or 30 mg ketorolac i.v. in the perioperative context (Rasmussen et al 2002, Barton 
et al 2002). Preliminary animal data suggest that parecoxib crosses the blood brain barrier (data 
on file, Pfizer Inc., USA). Celecoxib, also a highly selective COX-2 inhibitor, has been shown to 
be safe and efficacious for perioperative analgesic use in doses of, typically, 2 X 200mg p.o. per 
day (Straube et al 2005, Chen et al 2004) 
Both parecoxib and celecoxib are licensed as analgesics in the Netherlands. Parecoxib is 
approved for short-term use (e.g. perioperatively) in the Netherland at doses up to 40 mg twice 
daily. Celecoxib is approved for long-term oral use in the Netherlands, and the doses envisaged 
in the present study (2 X 200 mg/day) fall within the approved range.
Paravertebral block is a well-established technique of achieving unilateral blockade of the upper 
trunk of the body (Karmakar 2001). It has been shown to be effective in reducing pain after breast 
surgery (Buckenmaier et al 2003, Kairaluoma et al 2004). Ropivacaine is commonly used and 
described in the literature for paravertebral blockade (Karmakar et al 2005), and is registered for 
long-lasting local anaesthetic block in the Netherlands.
4. Trial Objectives
4.1. Primary objectives
•  To study the effect of the interaction of cyclooxygenase-2 (COX-2) inhibition (started 
preoperatively and continued 5 days into the postoperative period) and extended local 
anaesthetic blockade via paravertebral block on postoperative central sensitisation after 
breast surgery for malignancy
4.2. Primary endpoint
•  Neuroplasticity, e.g. central sensitisation as demonstrated by quantitative sensory testing, at 




•  To demonstrate that COX-2 inhibition also has favourable effects on postoperative clinical 
outcomes including acute and chronic pain, sickness syndrome, side-effects of analgesia and 
surgical complications
•  To demonstrate that the use of COX-2 inhibition in this context is safe and associated with an 
acceptable side-effect profile
4.4. Secondary endpoints
• Neuroplasticity at other time points after surgery
•  Acute and chronic clinical pain measures (pain scores, analgesic consumption, pain 
questionnaires)
•  Other pain outcome measures (incidence of phantom pain, pain maps, analgesia complications)
•  Surgical outcome measures (complications)




Prospective, randomised and double-blinded. Patients will be prospectively randomised into 
active (parecoxib and celecoxib) or placebo treatment groups. 
5.2. Study population
110 patients (n=55 per group) due to undergo elective first surgery for malignancy of the breast 
at UMC St. Radboud or Bernhoven Ziekenhuis in Oss.
5.3. Recruitment
The patients will be recruited during their initial surgical outpatient visit (mammacare). At this 
time preliminary verbal consent will be obtained and patients will receive detailed written patient 
information on the trial for further study and reflection. This information also warns the patient 
that they will be contacted later by telephone regarding possible participation in this trial. About 
one week later, patients will be contacted by telephone and asked if they wish to participate 
in the trial. At this time, patients will also be given more details on the study, and will have the 
opportunity of asking questions. If the patient agrees, he will be instructed as to the further 
organisation of the study. 
At the subsequent anaesthesia outpatient visit (for premedication) formal, written consent will 
be obtained by the anaesthesiologist and the research nurse, who will also answer questions 
and perform the demonstration and training necessary for quantitative sensory testing. Inclusion 
criteria include first elective breast surgery, as well as ability to comply with testing procedures 
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and to give informed consent. Recruitment will be organised in such a fashion as to ensure 
equal distribution of large and small breast surgery (i.e. mastectomy vs. lumpectomy) and 
nerve-damaging or non-nerve-damaging surgery (i.e. presence or absence of axilllary surgery) 
between the two treatment groups. 
5.4. Exclusion criteria
Previous breast surgery, any type of chronic pain syndrome, regular analgesic medication 
(including opioids, NSAIDs or COX-2 inhibitors) for the 2 weeks preceding surgery, pre-
existing central nervous system pathology (e.g. stroke, dementia), conditions predisposing to 
neuropathy (e.g. diabetes mellitus, alcohol abuse), inability to comply with testing procedures 
or to give informed consent, presence of contra-indications to COX-2 therapy (e.g. impaired 
renal or cardiac function (including angina pectoris), untreated hypertension, active or recent 
gastrointestinal ulceration), contraindications to paravertebral blockade.
5.5. Treatment intervention
After informed patient consent, patients will be randomised to either an active or placebo 
treatment group. On the morning of surgery, the patient will receive oral midazolam premedication 
(7.5 mg). In the operating theatre, the patients randomised to the active group will receive an i.v. 
injection of parecoxib 40 mg 30 minutes before the start of surgery. The injection will be repeated 
6 hours later. On the evening of the operation day patients will start celecoxib 2 X 200mg/d and 
continue this scheme until the morning of the fifth postoperative day. The placebo group will 
receive placebo injections and tablets according to the same regime. As the medication will be 
blinded, neither observers nor persons involved in patient management nor observers will be 
aware of which group the patients are in.
Anaesthesia
Patients can receive the usual oral benzodiazepine premedication on the evening before 
(e.g. oxazepam 10 mg p.o.) surgery. On the morning of surgery premedication will consist of 
midazolam 7.5 mg p.o.. Paravertebral blockade will be performed using the standard technique 
and 20 ml ropivacaine 0.75%. Before surgery, adequate local anaesthetic blockade will be tested 
for clinically using pin-prick. Unsuccessful block will lead to exclusion of the patient from the 
study. General anaesthesia will be via a standard scheme, with anaesthesia being induced using 
propofol 2-3 mg/kg, fentanyl 3 µg/kg and rocuronium 0.5 mg/kg. Anaesthesia maintenance 
will be via air/oxygen (40%) and isoflurane. If the procedure lasts longer than 45 minutes from 
intubation, further analgesic supplementation with fentanyl 1 µg/kg will be permitted at 45 minutes 
and then at further 45 minute intervals. The last dose of fentanyl should be given no less than 
45 minutes before the end of surgery. No further myorelaxant supplementation will be given and 
no antagonisation will be performed at the end of surgery. The maintenance of a comparable 
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and acceptable depth of anaesthesia using isoflurane will be guided by keeping haemodynamic 
values to within 20% of preoperative baseline values. 
Analgesia
In the recovery room, patients will be titrated to VAS≤3 by the recovery room nurse using 3 
mg intravenous increments of piritramide as soon as they complain of pain. Standard 
postoperative analgesia from this time onwards will consists of a fixed paracetamol scheme 
(4 X 1g paracetamol/day) together with on-demand tramadol (as drops, maximum 300 mg/
day) up to day 5 postoperatively. Postoperative nausea and vomiting will be treated by 1) 10 
mg metoclopramide i.v., 2) 1.25 mg droperidol i.v. and 3) 4 mg ondansetron i.v. (in that order of 
escalation).
5.6. Measures and endpoints
Perioperative Measures 
1.  Time to first request for analgesia in recovery room and total titration dose (piritramide, once 
only!)
2.  VAS (100 mm unanchored visual analogue scale) for somatic and phantom pain intensity 
(both: at rest, on coughing, on moving arm)
3.  Cumulative on-demand tramadol consumption
4.  Standard haemodynamic measures, temperature
5.  Quantitative sensory testing (QST) by transcutaneous electrical and mechanical stimulation
6.  Short MPQ (Dutch language version) for somatic and phantom pain
7.  Complications, need for drop-out (also an endpoint), patient satisfaction and well-being 
(including nausea/vomiting, opioid symptom distress score [SDS] and clinically meaningful 
events score [CME])
Additional Documentation
Preoperatively we document smoking habits of the patients as well as demographic variables. 
Any postoperative complications will be noted. At each data collection point, complications 
attributable to COX-2 inhibitors will be looked for (allergy, bleeding, gastrointestinal or renal 
complications). Furthermore, the opioid Symptom Distress Score (SDS) and the Clinically 
Meaningful Events Score (CME) will be collected at each data collection point.
5.7. Times of measures
• At formal recruitment before surgery
•  On leaving recovery unit postoperatively (inpatient; not measures 6-7)
• 5, 15 days postoperatively (outpatient)
•  1, 3, 6 and 12 months post-mastectomy (outpatient)
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•  12 months post-mastectomy, we will additionally collect details on
    i) surgical complications
    ii) details of adjuvant therapy (chemotherapy, radiotherapy, hormone therapy)
    iii) wound healing and disease state (recurrence, metastases, progression)
5.8. Blinding
The pharmacy of UMC St. Radboud/Ziekenhuis Bernhoven will hold and administer the 
randomisation scheme for the trial. Parecoxib and celecoxib (active or placebo) will be supplied 
by the hospital pharmacy. 
5.9. Power analysis
Based on data from previous postoperative QST studies (Wilder-Smith et al 1996, 1998) we can 
expect pain tolerance thresholds in thoracic dermatomes five days after surgery to be about 8.1 
mA with a standard deviation of about 4.5 mA. Sample size calculation based on these data for a 
Type 1 Error (alpha) of 0.05 and a Power (beta) of 80% predicts that we should be able to detect a 
clinically relevant change in paint tolerance thresholds of one third with a sample size per group 
of 45 patients. Assuming a drop-out rate of 20-25%, the sample size of n=55 per group should 
thus be large enough to detect a clinically relevant reduction of ca. one-third in the pain tolerance 
threshold (compared to the other group) at 5 days postoperatively.
5.10. Analysis and statistics
The following aspects will be analysed within and between the treatment groups:
•  topography of neuroplasticity
•  postoperative time course of neuroplasticity
•  postoperative time course of clinical pain measures (VAS, MPQ, analgesic consumption) and 
other clinical outcomes scores (e.g. opioid symptom distress scores)
•  presence/absence/severity of phantom pain, pain complications, medical outcomes
•  QST vs. pain measures; early QST/pain measures vs. late QST/pain measures vs. medical/
pain outcomes
•  effects of factor scoring for extent of axillary/breast surgery
Statistical analysis, after testing for normal distribution of data, will be via repeated measures 
ANCOVA (covariant = initial threshold; factors: scoring for extent of axillary/breast surgery, 
treatment group, time, measurement site) for change in thresholds, VAS value (somatic/phantom, 
at rest/on movement) and analgesia consumption. Demographic data will be compared using 
Student’s t-testing; ordinal data (e.g. scores) will be compared via Kruskal-Wallis ANOVA. 





6.1. Individual stop criteria
Individual wishing to leave the study for any reason whatsoever will leave the study protocol, as 
will patients who cannot be satisfactorily managed within the study protocol (lack of therapeutic 
success, excessive side-effects, major surgical complications). The reasons for leaving the study 
will be documented, and patient outcome will continue to be documented (i.e. for intention-to-
treat analysis).
7. Ethics
7.1. Ethical conduct of trial
The study will conform to the Geneva and Helsinki declarations and will be conducted according 
to GCP guidelines. The study design will be approved by the appropriate regional ethics 
committee.
7.2. Subject information and consent
Initial contact for recruitment will be via the oncological surgeon (in the surgical outpatient 
clinic, mammacare). At this time the patient will receive an information sheet and be warned 
of the possibility of a phone call about study participation. After a reflection time of at least 24 
hours, patients will be contacted by phone to obtain preliminary verbal consent. At the time 
of the subsequent anaesthesia outpatient clinic visit (for premedication) the anaesthesiologist 
and research nurse will answer any further questions and obtain formal, written consent from 
the patient. The study nurse will at this time perform the necessary demonstration and training 
necessary for quantitative sensory testing. 
7.3. Study drugs
The safety record of COX-2 selective inhibitors is well proven, both acutely and chronically. 
Parecoxib is approved for perioperative acute use in the Netherlands in the dosage proposed 
(2X40mg); celecoxib is also approved in the Netherlands for chronic analgesic use at the 
proposed doses (2 X 200 mg per day).
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Chronic pain after surgery, referred to as persistent postsurgical pain (PPSP), is an important 
condition leading to significant symptom burden and reduced quality of life in affected 
individuals.1 PPSP is broadly recognized as pain lasting >3 months after surgery. The condition is 
common, with prevalence estimates ranging from 10% to 50% of all postsurgical patients.1 High-
risk procedures include breast surgery, thoracotomy, limb amputation, and inguinal hernia 
repair.1 PPSP is relatively refractory to treatment and thus has generated interest in potential 
preventive strategies and treatments.2 A better understanding of which patients develop 
PPSP would help identify the subset of patients who are likely to require additional treatment 
to optimize their perioperative and postoperative pain management. However, the complexity 
and individuality of the human response to pain pose significant challenges in making accurate 
predictions of PPSP development. As Raja and Jensen3 pointed out, we are currently not better 
than the weather forecaster in predicting an individual patient’s postoperative pain experience. 
Although the differences between predicting PPSP and predicting the weather are very profound, 
we argue that several techniques used in weather prediction could actually serve as an example 
for attempts to better predict PPSP. We hypothesize that at least 3 techniques used in weather 
prediction may be relevant in an attempt to improve our ability to predict PPSP: (1) application 
of recent mathematical, statistical, and computational advances; (2) the construction of a 
model, taking into account the initial state of the system and the forecast range; and (3) ongoing 
improvement of algorithms by evaluating the success and failure of predictions.
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APPLICATION OF RECENT MATHEMATICAL, STATISTICAL, AND 
COMPUTATIONAL ADVANCES
Weather forecasters were once the unfortunate subjects of countless jokes. Predicting 
the weather from multiple interacting meteorological factors that are greatly influenced by 
underlying geography seemed no better than extracting a forecast from a cloudy crystal ball. The 
complexity and individuality of the human response to the nociception of surgery pose similar 
hurdles to making accurate predictions of PPSP development. But access to huge amounts of 
data, refinement of mathematical models, and enhanced computing power have transformed 
predictive meteorology,4 and the same may apply to the predicting of PPSP.
The development of PPSP has been associated with a wide range of factors including pain 
processing, demographic factors, treatment factors, psychosocial factors, and genetic/
epigenetic factors.1,3 Conventional logistic regression approaches are unable to incorporate 
the rapidly expanding set of available data nowadays, let alone the genetic, proteomic, and 
metabolomic data expected to be available for analysis and prediction of PPSP in the near 
future. Machine-learning classifiers are algorithms that can autonomously integrate and learn 
from complex datasets with many hundreds of variables.5 Machine-learning techniques are used 
on a daily basis to solve prediction problems such as handwriting recognition, fraud detection, 
and e-mail spam filtering. These algorithms use a variety of mathematical approaches and are 
often more computationally efficient and accurate when using very large datasets (big data) 
with complex distributions that do not conform to the assumptions of parametric methods like 
logistic regression.5 Therefore, machine-learning classifiers may offer a solution to the vexing 
challenge of predicting PPSP. Tighe et al6 recently demonstrated the feasibility of this approach 
by using machine learning on readily available information in the electronic medical record 
to predict which individual patients are at risk of severe acute postoperative pain, which is a 
known risk factor for PPSP.1 The model used by Tighe et al6 was based on routinely collected 
clinical data but performed similarly in predicting acute moderate to severe postoperative 
pain to models from studies specifically gathering data to predict acute moderate to severe 
postoperative pain using traditional statistical methods.6 Another example of machine learning 
in the context of pain prediction is the successful application of machine learning to predict the 
response to postoperative opioid medication using preoperative electroencephalography (EEG) 
parameters.7,8 Gram et al7 recorded clinical parameters and EEG during rest and tonic pain in 
81 patients the day before total hip replacement surgery. Postoperative pain treatment consisted 
of oral oxycodone and intravenous piritramide via patient-controlled analgesia. Patients were 
stratified into responders and nonresponders based on pain ratings during 24 hours after surgery. 
Potential predictive preoperative parameters were analyzed using machine learning to predict 
the individual response to opioid analgesia. After surgery, they found a large interindividual 
variation in pain ratings, even though patients were treated using patient-controlled analgesia. 
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The machine-learning prediction model found that preoperative EEG analysis during tonic pain 
was able to predict responders to opioid analgesia with an accuracy of 65%, indicating that it 
may be used as an objective preoperative biomarker of postoperative opioid response. In the 
field of diabetes research, Zeevi et al9 recently reported on a machine-learning approach to the 
complex problem of elevated postprandial glucose concentrations. In an 800-person cohort, they 
found markedly high variability in the glucose response to identical meals between individuals, 
suggesting that universal dietary recommendations have limited value. Using gut microbiome 
measurements, blood parameters, and other measurements of patients’ glucose physiology, 
they constructed a machine-learning algorithm to predict personalized glycemic responses 
to meals. Subsequently, they used this algorithm to provide individual food recommendations 
(such as chicken recommended for 1 person, but withheld from another) and demonstrated 
significantly lower postprandial glucose concentrations and concomitant changes in gut 
microbiota. Similarly, it is conceivable that machine-learning approaches applied to different, 
high-resolution, specifically for PPSP prediction gathered parameters such as data from EEG, 
treatment factors, psychosocial factors, and epigenetic and genetic factors, have the potential 
to create more accurate, individualized predictions of PPSP. Such models may even be used to 
tailor specific perioperative treatments based on individual patient characteristics. At present, 
there is moderate evidence for different “antihyperalgesic” drugs and regional anesthesia as 
preemptive analgesia in the context of specific procedures.10 However, most trials studying 
prevention of PPSP have been underpowered with inadequate patient follow-up.10 More data on 
the effect of preemptive analgesia on PPSP will impact the ultimate relevance of PPSP prediction.
Although machine learning can improve the accuracy of prediction over the use of conventional 
regression models by capturing complex, nonlinear relationships in the data, it cannot squeeze 
out information that is not present in the data. Most big data efforts thus far have mostly focused 
on using readily available information from electronic health records or insurance data.5,6 These 
data are easy and inexpensive to obtain, but using these types of low-resolution data that were 
collected to serve a different purpose may lead to construct validity issues.5 It would be more 
worthwhile to apply these innovative analytics to data from traditional high-resolution sources and 
combine them with new sources, as demonstrated in several of the aforementioned studies,7–9 
although an obvious trade off in collecting more specific predication data is that it would likely 
require additional resources. Ultimately, the patient burden and resources required for specific 
high-resolution testing to predict PPSP need to be weighed against the treatment implications of 
accurate prediction of PPSP. In the context of procedures that are overall associated with a low 
risk of PPSP and/or no known effective preemptive treatments, it may at present be more feasible 
to restrict prediction models to readily available data.
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THE CONSTRUCTION OF A MODEL, TAKING INTO ACCOUNT THE INITIAL 
STATE OF THE SYSTEM AND THE FORECAST RANGE
An improvement in the prediction of weather has been the realization that small perturbations to 
the initial conditions in unstable systems may result in vastly different forecasts on a long-term 
basis, limiting predictive performance. This concept, also known as “chaos theory,” and the 
recognition that forecasts have system state–dependent limits of predictability, has led to the 
development of models to estimate the uncertainty of forecasts.11 The chaos theory concept is 
often illustrated using the metaphorical example of the “butterfly effect,” stating that the path and 
time of a tornado formation can be influenced by minor perturbations such as the flapping of the 
wings of a distant butterfly several weeks earlier.
Several recent systematic reviews have focused on the preoperative prediction of postoperative 
pain12–15 using psychophysical testing. Psychophysical testing, also called quantitative sensory 
testing, consists of recording the perceived pain to different standardized stimuli to obtain 
measures of pain processing. Patients prone to develop PPSP have been shown to exhibit a 
pronociceptive pain processing, as evidenced by higher perceived pain to the same standardized 
stimulus (hyperalgesia) and impaired pain inhibitory modulation, when compared to patients 
who will not develop PPSP.14 Preoperative psychophysical testing is currently indeed one of 
the most promising methods to predict PPSP12 and may predict 4%–54% of the variance in 
acute postoperative pain,12,14 which is an important risk factor for PPSP.1 However, from a clinical 
standpoint, such prediction is not sufficient to predict an individual patient’s PPSP development 
and justify invasive or medical preventative strategies.3 Although highly accurate preoperative 
prediction of long-term PPSP would indeed be the “silver bullet” in terms of initiating potential 
preventative perioperative treatment strategies, such prediction may not be feasible at present.
In the context of PPSP, the significant perturbation that is applied to a patient’s pain processing 
system by the nociception of surgery may limit the predictability of PPSP using preoperative 
models. It is known that severe acute postoperative pain and specific acute postoperative 
pain trajectories are predictive of PPSP.1 Moreover, some studies have shown that treatment of 
acute postoperative pain with different analgesic regimes may prevent subsequent PPSP in a 
substantial fraction of patients.16 It may thus be more feasible to focus PPSP prediction models 
on the acute postoperative period, when the patient’s pain processing system has been affected 
by the perturbation of surgery and psychophysical measurements may show a shift in pain 
processing toward a pronociceptive pain response, which is likely associated with an increased 
risk of PPSP. Along these lines, we have previously reported lower pressure pain tolerance 
thresholds (Figure 1) and higher pain scores (Figure 2) very early after surgery in women who 
developed PPSP at 12 months after breast cancer surgery.17
CHAPTER 6
146
Figure 1. Logistic probability plot of persistent postoperative pain 12 mo postoperatively based on change 
in pressure pain threshold at postoperative day 5 versus preoperative baseline. Change in pressure pain 
thresholds was measured in 94 women undergoing breast cancer surgery, and persistent pain was defined 
as a pain score of >30 mm on visual analog scale at 12 mo postoperatively. Eleven patients (12%) developed 
persistent postsurgical pain. This figure is a reanalysis from van Helmond et al.17
Figure 2. Logistic probability plot of persistent postoperative pain 12 mo postoperatively based on the 
clinical pain score reported during arm movement at postoperative day 5. VAS was measured in 94 women 
undergoing breast cancer surgery, and persistent pain was defined as a pain score of >30 mm on VAS at 12 
mo postoperatively. Eleven patients (12%) developed persistent postsurgical pain. This figure is a reanalysis 
from van Helmond et al.17 VAS indicates visual analog scale.
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In agreement with the presented theory that the baseline pain system state of patients undergoing 
surgery may not allow for long-term predictions of PPSP, preoperative pain thresholds were 
not predictive of PPSP,17 which is consistent with a similar study on PPSP after breast cancer 
surgery.18 However, in the context of other types of surgery, a pronociceptive pain phenotype 
preoperatively has been reported to be predictive of PPSP.14 Most of these studies were conducted 
in the context of orthopedic joint surgery and represent a very different patient population. In the 
orthopedic population, patients have often suffered from ongoing pain and nociceptive input for 
a prolonged time preoperatively, which may have led to a sensitized pain system and enhanced 
pain message transmission even before surgery. Conversely, patients undergoing surgery for 
breast cancer are highly unlikely to have suffered from significant pain preoperatively and are 
consequently unlikely to express a change in their pain system preoperatively.
Along these lines, it seems likely that a number of parameters have different predictive value 
for development of PPSP at different perioperative time points and these may again be 
variable for different surgical procedures. Additional and larger studies are needed to examine 
what perioperative time points and prediction models are appropriate for specific surgical 
procedures. Similarly, a recent initiative has been taken by the Procedure-Specific Postoperative 
Pain Management group, consisting of experts analyzing existing evidence, to provide different 
specific recommendations for postoperative pain control for different surgical procedures.19 More 
evidence on treatments capable of preventing PPSP for different surgical procedures will help 
allocate adequate perioperative treatments to patients at high risk of developing PPSP, as 
identified by prediction models.
ONGOING IMPROVEMENT OF ALGORITHMS BY EVALUATING THE 
SUCCESS AND FAILURE OF PREDICTIONS
A central component to the advancement of weather prediction over the past few decades 
has been that weather prediction performance is evaluated objectively daily and globally, so 
that success and failure of forecasts are accurately known and pathways to improve predictive 
performance can be effectively tested.20 In the context of predicting PPSP, most clinical studies 
focus on 1 individual factor or on a set of factors, in a single-center prospective or retrospective 
study design. The focus on individual significant factors, which contribute relatively little to 
the overall PPSP variation, is problematic from a clinical standpoint, since a small added risk 
cannot satisfactorily justify additional preventive treatments. Moreover, most individual factors 
that demonstrate explanatory statistical significance have not been used in actual dedicated 
subsequent prediction studies and most studies have not been validated in independent patient 
cohorts. It would be more valuable to take a comprehensive approach, combining many clinical, 
demographic, psychosocial, genetic, and neurophysiological factors in a single prediction model 
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using the aforementioned machine-learning approaches and to refine this model in an ongoing 
iterative manner. Improving a comprehensive model in a prospective iterative manner will likely 
allow for the identification of new pathways to increase predictive performance. It is conceivable 
that building such a model will concomitantly lead to more insight into the pathophysiological 
pathways through which PPSP arises, by generating testable hypotheses based on the found 
predictors. Because it is impossible to infer causality from such correlations, it will still be 
necessary to run conventional trials to test any strong prediction hypothesis that comes out of a 
machine-learning process. Applying innovative analysis approaches to all relevant data available 
will by no means abolish the need for controlled research on single factors but will likely catalyze 
its focus in a certain direction. The current lack of understanding of the pathophysiology of PPSP 
is in stark contrast with weather models, which are at the heart based on well-understood but 
nonlinear equations involving the conservation of mass, momentum, and energy.
At this point in time, most clinicians would not want to emulate weather forecasters and be 
asked to predict an individual’s PPSP risk based on factors such as their pain processing profile, 
psychosocial factors, or genetic factors. However, when combined with a machine-learned 
algorithm focused at different postoperative time points, incorporating all individual factors, 
prediction may be less daunting. Such models could be used to provide individualized decision 
support to clinicians based on learning from trajectories in similar patients in the past. In the era 
of “big data” science, in which we can measure an enormous number of parameters, harnessing 
the most-predictive aspects of highly dimensional data will likely be very powerful.
CONCLUSIONS
In conclusion, prediction of PPSP may benefit from different techniques regularly used in weather 
prediction. First, prediction of PPSP may be enhanced by the application of recent mathematical, 
statistical, and computational advances. Second, prediction of PPSP should take into account 
the time scale and the stability of the initial pain processing system on which the model is 
developed. Third, comprehensive PPSP prediction models should be improved in an ongoing 
prospective, iterative manner by evaluating success and failure of predictions. Future studies 
need to test the hypothesis that PPSP prediction can be improved along the methods outlined 
in this article.
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General conclusions and discussion. 
Recommendations for clinical 





In this PhD thesis we set out to investigate the following pertinent questions related to persistent 
postsurgical pain (PPSP) after breast cancer surgery:
 • What is the prevalence of PPSP after breast cancer surgery?
 •  What are demographic and clinical risk factors for PPSP after breast cancer surgery?
 •  Are preoperative quantitative sensory testing (QST) measures related to PPSP after 
breast cancer surgery and PPSP after other types of surgery?
 •  How can QST best be used in research on PPSP after breast cancer surgery?
 •  Can perioperative cyclooxygenase-2 (COX-2) inhibition reduce postoperative pain 
sensitization after breast cancer surgery?
 •  Can perioperative COX-2 inhibition reduce the incidence of PPSP after breast cancer 
surgery?
 •  What future directions in research may be helpful in improving identification and 




PREVALENCE OF PPSP AFTER BREAST CANCER SURGERY 
In Chapter 2, we presented a large retrospective cohort study (n= 492) into the prevalence of 
PPSP after breast cancer surgery.1 We identified that approximately 36% of patients suffered from 
varying degrees of PPSP more than six months after breast cancer surgery. Patients reporting 
pain related to surgery were classified into categories based on their reported visual analogue 
scale (VAS) pain score: 1 – 29 mm was considered “mild pain” and 30 – 100 mm was considered 
“moderate to severe pain”. We found that most patients suffering from PPSP suffered from mild 
pain (25% of all patients undergoing surgery), whereas a smaller subset suffered from moderate 
to severe pain (11% of all patients undergoing surgery). These rates are similar to findings from 
other recent large cohort studies on PPSP after breast cancer surgery.2,3
DEMOGRAPHIC AND CLINICAL RISK FACTORS FOR PPSP AFTER BREAST 
CANCER SURGERY
In the study presented in Chapter 2, we also investigated demographic and clinical risk factors 
associated with suffering from PPSP after breast cancer surgery. We performed ordinal logistic 
regression between potential risk factors of PPSP after breast cancer surgery and the stratified 
PPSP intensity outcome in patients at long-term follow-up (no-pain/mild pain/moderate-severe 
pain). In univariable analyses age, body mass index (BMI), surgery type (lumpectomy vs. 
mastectomy), axillary lymph node status (dissection vs. no dissection), breast cancer disease 
stage, reoperation status (reoperation vs. not a reoperation), chemotherapy status (chemotherapy 
vs. no chemotherapy), and radiotherapy status (radiotherapy vs. no radiotherapy) were 
identified as risk factors for PPSP.1 In a multivariable model, risk factors age and BMI remained 
independently associated with PPSP outcome. In other research on risk factors of PPSP after 
breast cancer surgery, age,4 lumpectomy vs. mastectomy,5 axillary lymph node dissection vs. no 
dissection,6 higher disease staging,3 reoperation,7 chemotherapy,8 and radiotherapy9 have been 
identified as being associated with PPSP consistent with our findings.  
Our study was the first to report a relationship in a multivariable adjusted model between higher 
BMI and PPSP following breast cancer treatment. We found an increased risk of PPSP of around 
4% per 1 kg/m2 increase in BMI. We hypothesized that the relationship of BMI with PPSP may 
be mediated by low-grade inflammation and sensitized central pain processing through the 
release of pro-inflammatory and insulin resistance-inducing substances from visceral adipose 
tissue. Observational QST studies have demonstrated that individuals with obesitas exhibit 
decreased pain threshold to electrical stimuli10 as well as mechanical stimuli.11 In fibromyalgia, 
BMI is significantly related to the number of positive tender points (painful points upon manual 
palpation) as well as pain rating of the tender points when palpated.12 The consideration that 
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inflammation plays a role in pain sensitization mechanisms and PPSP after breast cancer surgery 
was further investigated in a prospective randomized controlled study in Chapter 5.
RELATIONSHIP OF PREOPERATIVE QUANTITATIVE SENSORY TESTING 
MEASURES WITH PERSISTENT POSTOPERATIVE PAIN AFTER BREAST 
CANCER SURGERY AND OTHER TYPES OF SURGERY
To assess the state of science concerning the relationship of preoperative QST in breast cancer 
surgery and other types of surgery we performed a systematic literature review in Chapter 3. 
Previous systematic reviews had found that patients who preoperatively perceive more pain 
on QST (hyperalgesia), or have impaired endogenous analgesia, experience more acute 
postoperative pain.13,14 Higher acute postoperative pain has been shown to be a risk factor for the 
development of PPSP.15,16 Along these lines, it has been suggested that preoperative QST may be 
useful to predict PPSP clinically.17 However, the specific relationship between preoperative QST 
and PPSP had not been systematically reviewed. Because of the strong relationship between 
preoperative QST measures and acute postoperative pain,14 we hypothesized that preoperative 
QST measures are strongly associated with PPSP. We identified only one study that assessed 
the relationship between QST measures and PPSP after breast cancer surgery.18 In that study 
no relationship was found between preoperative QST measures and PPSP. We also reviewed 
the literature systematically for reported relationships between preoperative QST measures and 
PPSP in any other types of surgery. We found that preoperative CPM,19-21 temporal summation 
of pain,22-25 and pressure pain threshold26-28 were most frequently significantly associated with 
PPSP with variable strengths of association. QST methods were found to vary widely between 
research groups, which limits the generalizability of conclusions to the specific QST methods 
used and their associations. Standardization of protocols across international research groups 
would assist in effective investigation of the association between QST measures and PPSP after 
breast cancer surgery or other types of surgery. 
USE OF QUANTITATIVE SENSORY TESTING IN RESEARCH ON PPSP AFTER 
BREAST CANCER SURGERY
To facilitate the assessment of pain thresholds in clinical patients undergoing breast cancer 
surgery we detailed a relatively short standardized QST protocol in Chapter 4. Previous 
standardized QST protocols, such as the German Research Network on Neuropathic Pain 
protocol,29 are quite extensive and may not be suitable for long-term follow-up with repetitive 
measurements in patients undergoing breast cancer surgery in the context of a clinical trial. 




endogenous analgesia in patients with breast cancer.30 To facilitate the implementation of this 
protocol in other institutions we described the protocol using a standard operating procedure 
with illustrations. Additionally, the entire step-by-step protocol was demonstrated in a detailed 
video accompanying the methodology publication to further facilitate dissemination of the QST 
methodology that we developed for use in patients undergoing breast cancer surgery. This article 
is highly accessed (~5000 times < 2 years), demonstrating the high need for the standardization 
of QST protocols in order to have comparable data about PPSP between different prospective 
studies and research institutions.
PERIOPERATIVE COX-2 INHIBITION TO REDUCE POSTOPERATIVE 
SENSITIZATION AND PPSP AFTER BREAST CANCER SURGERY
In Chapter 5 we presented a randomized controlled trial assessing the effect of peri-operative 
COX-2 inhibition on sensitization of pain processing and PPSP after breast cancer surgery.31 
This study investigated the potential risk factor of inflammation identified in Chapter 2, while 
applying best practices related to QST in the context of surgical research that were identified 
and demonstrated in Chapters 3 & 4. 138 women undergoing breast cancer surgery under 
general anesthesia with paravertebral block were randomized to receive perioperative COX-
2 inhibition or placebo. We assessed which women developed PPSP up to 12 months after 
surgery. Preoperatively, early postoperatively, and up to 12 months postoperatively, we also 
determined electric and pressure pain tolerance thresholds. We found no differences in pain 
tolerance thresholds or in PPSP between the COX-2 inhibition and placebo groups, indicating 
that COX-2 inhibition has limited value in preventing sensitization and PPSP after breast cancer 
surgery. Consistent with observational studies on PPSP after breast cancer surgery,32,33 we found 
that women who developed PPSP demonstrated sensitized processing of pain, as evidenced by 
generalized lower pressure pain tolerance thresholds when compared to women not developing 
PPSP. These differences were evident early after surgery (5 days after surgery).  
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RECOMMENDATIONS FOR CLINICAL PRACTICE, FUTURE RESEARCH, 
EDUCATION, AND SOCIETAL IMPACT
Several recommendations were identified over the course of the present work. 
Clinical recommendations
 •  We recommend early postoperative assessment for risk estimation of PPSP 
after breast cancer surgery
In our randomized controlled trial we did find that patients who eventually developed PPSP 
expressed pain sensitization and increased acute postoperative pain as early as 1 and 5 days 
after surgery when compared to patients who did not develop PPSP.31,34 These findings are 
entirely consistent with the presumed important role of pain sensitization early after surgery 
in PPSP development35 and studies highlighting the relationship between early postoperative 
pain trajectories and PPSP after different types of surgery.36,37 It may thus be feasible to focus 
on identification and treatment of patients at high risk of PPSP development in the acute 
postoperative period, when the patient’s pain processing system has been affected by the 
perturbation of surgery and QST and pain measurements may show a shift in pain processing 
toward a sensitized pain response, which is likely associated with an increased risk of PPSP. 
Moreover, some studies have shown that treatment of acute postoperative pain with different 
analgesic regimes may prevent subsequent PPSP in a substantial fraction of patients.38 These 
findings provide a framework to clinically identify patient at high risk of PPSP by closely monitoring 
acute postoperative pain sensitivity and pain. 
 •  We do not recommend preoperative quantitative sensory testing to predict 
PPSP after breast cancer surgery 
In Chapter 6 we described that most studies on the prediction and prevention of PPSP after 
breast cancer surgery and other types of surgery have focused on preoperative identification 
of patients at risk of developing PPSP. QST studies have shown that patients prone to develop 
more severe acute postoperative pain after different types of surgery have been shown to 
exhibit pronociceptive pain processing, as evidenced by higher perceived pain to the same 
standardized stimulus (hyperalgesia) and impaired pain inhibitory modulation on QST, when 
compared with patients who experience less severe postoperative pain.14 Preoperative QST 
may predict 4%–54% of the variance in acute postoperative pain,14 which is an important risk 
factor for PPSP after various types of surgery other than breast cancer. Although highly accurate 
preoperative prediction of long-term PPSP would indeed be the “silver bullet” in terms of initiating 
potential preventative perioperative treatment strategies, such prediction appears not feasible at 




presented in Chapter 5 and in the systematic review presented in Chapter 3 we did not find 
a relationship between preoperative QST measures and PPSP after breast cancer surgery. In 
the context of PPSP after breast cancer surgery, the significant perturbation that is applied to a 
patient’s pain processing system by the nociception of surgery may limit the clinical predictability 
of PPSP using preoperative methods.34 
 •  We do not recommend perioperative COX-2 inhibition to prevent persistent 
pain after breast cancer surgery
Our randomized controlled trial assessed the effect of peri-operative COX-2 inhibition on 
sensitization of pain processing and PPSP after breast cancer surgery.31 We found no differences 
in pain tolerance thresholds or in PPSP between the COX-2 inhibition and placebo groups, 
indicating that COX-2 inhibition has limited value in preventing sensitization and PPSP after 
breast cancer surgery.
Research recommendations
 •  BMI should be investigated as a potentially modifiable risk factor for PPSP 
after breast cancer surgery
Our large cohort study was the first to report a relationship in a multivariable adjusted model 
between higher BMI and PPSP following breast cancer treatment.1 At present, there is no 
prospective research assessing the effects of weight loss on PPSP. Additional research should 
examine the effect of dietary and physical therapy programs on persistent postoperative pain 
conditions. This information could help clinicians determine the best strategy to manage or 
prevent pain in patients with obesitas. In our specific population, female patients with breast 
cancer undergoing cancer treatment, recommendations to restrict calories must take into 
consideration whether weight loss is possible during treatments such as chemotherapy. 
Moreover, breast cancer surgery can obviously not be postponed to allow for preoperative weight 
loss. Interestingly, obesity is associated with poorer breast cancer survival, and this relationship 
between BMI and survival is observed both in preoperative studies and postoperative studies 
(> 12 months).39 Fasting is currently being assessed as a method to ameliorate side effects of 
chemotherapy40 and to improve response to chemotherapy41 and radiotherapy.42 In this context, 
there has been a call for randomized clinical trials to test interventions for weight loss and 
maintenance on survival in women with breast cancer.39
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 •  Future studies on PPSP should utilize a comprehensive biopsychosocial 
preoperative assessment in patients undergoing breast cancer surgery 
In Chapter 6 we acknowledged that the development of PPSP has been associated with a 
wide range of factors including pain processing, demographic factors, treatment factors, 
psychosocial factors, and genetic/epigenetic factors.43,44 Our studies1,31 did not incorporate 
the entire spectrum of potentially important variables and inclusion of such variables may add 
important information. A comprehensive, interdisciplinary, treatment approach is increasingly 
important in the context of many cancers. Due to advances in detection and progressively 
more complex treatments, cancer-specific mortality for many prevalent cancers has decreased 
substantially in developed countries.45 PPSP is just one problem within a range of conditions 
associated with ‘cancer survivorship’; other frequently occurring persistent problems are 
lymphoedema, fatigue, cognitive changes, cardiotoxicity, and psychosocial issues (e.g., cancer 
recurrence, body image concerns, and anxiety).46 The cancer post-treatment survivorship phase 
of treatment is historically understudied. Broad, interdisciplinary efforts are needed to improve 
care in the post-treatment phase. 
 •  Future studies on PPSP prediction should explore the utility of advanced 
data science methods
Conventional logistic regression approaches are unable to incorporate the rapidly expanding set 
of available data nowadays, let alone the genetic, proteomic, and metabolomic data expected 
to be available for analysis and prediction of PPSP after different types of surgery in the near 
future. Machine-learning classifiers are algorithms that can autonomously integrate and learn 
from complex datasets with many hundreds of variables.47 These  algorithms use a variety of 
mathematical approaches and are often more computationally efficient and accurate when using 
very large datasets (big data) with complex distributions that do not conform to the assumptions 
of parametric methods like logistic regression.47 Therefore, machine-learning classifiers may 
offer a solution to the vexing challenge of predicting PPSP. Tighe et al.48 recently demonstrated 
the feasibility of this approach by using machine learning on readily available information in 
the electronic medical record to predict which individual patients are at risk of severe acute 
postoperative pain, which is a risk factor for PPSP.43
 •  Future studies on PPSP prediction should test pre-defined, appropriately 
powered, hypotheses
In Chapter 3 we described that it is important to note that many previous studies on PPSP 
prediction to date have moderate or high risk of bias in multiple quality domains.49 The majority 




after different types of surgery to date did so without a prespecified primary hypothesis or 
an associated power calculation. In addition, many studies have assessed a multitude of 
relationships in a limited number of subjects. These conditions allow for the possibility that some 
of the current knowledge in this area is based on negative findings concerning a relationship 
between preoperative QST and PPSP that are type II errors and some positive findings that 
are type I errors.50 Future studies on PPSP prediction and prevention should address specific 
hypotheses with associated power calculations for primary outcome measures.51  
 •  Future studies on PPSP prediction should include independent validation 
cohorts 
As described in Chapter 3 almost all studies on PPSP prediction after breast cancer surgery and 
other types of surgery have been based on explanatory analyses in the entire study cohort without 
validation testing in an independent cohort. To establish any preoperative QST measurement or 
other clinical measure as a useful prospective predictor of PPSP, future studies should either 
focus on validating previously established associations or include both model development 
and validation cohorts for analysis.52,53 Such studies would also help in assessing if there is 
potentially causality between findings on preoperative characteristics and PPSP development. 
These studies could subsequently lead to studies on preventive measures in patients at high risk 
of PPSP development. 
Education recommendations
 •  Physicians and patients should be better educated about the risk and 
pathophysiology of PPSP after breast cancer surgery
Patients who suffer from PPSP may assume that something went wrong, or that the surgeon 
made a mistake. It has been shown that patients who belief that they were  injured exhibit lower 
pain thresholds and tolerance, general deconditioning, and reduced activity.54 Patients who 
attribute blame for their pain report more behavioral disturbance and distress, a poor response 
to treatments, and have lower expectations of the success of future treatments.55 PPSP in the 
majority of cases is not related to any medical error and appears to be an inevitable consequence 
of surgery in a proportion of cases.56 Education of patients and doctors about the problem of 




 •  Improved stratification for and treatment of patients at high-risk for PPSP 
after breast cancer surgery holds potential to improve healthcare efficiency 
and to reduce healthcare cost while improving quality of life for patients 
PPSP, once established, is difficult to treat.57 In addition to loss of quality of life in affected 
patients,58 PPSP constitutes a significant societal burden in the form of healthcare cost and lost 
productivity.57 This thesis provides a starting point for research and clinical methods to identify 
breast cancer patients that are likely at risk of developing PPSP. Even though our studies indicate 
that preoperative prediction is challenging, the results suggest that very early postoperative 
prediction of PPSP is feasible. If it is possible to prevent PPSP by early identification and 
aggressive treatment of acute postoperative sensitization and pain, substantial patient and 
societal burden can be prevented.
GENERAL CONCLUSION 
In this thesis we investigated the significant clinical problem of PPSP after breast cancer surgery 
with a focus on risk factors, prediction, and potential prevention of PPSP based on mechanisms 
believed to underlie PPSP development. We identified BMI as a novel demographic risk factor 
for PPSP after breast cancer surgery, but overall preoperative prediction of PPSP after breast 
cancer surgery using risk factors and QST methods was found to be challenging. COX-2 
inhibition around surgery was not helpful in preventing PPSP after breast cancer surgery. On 
the contrary, we found that early postoperative prediction using QST methods and clinical signs 
holds promise. We provided a framework for further studies on early postoperative PPSP risk 
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The aim of this thesis research was to investigate mechanism-based prediction and prevention 
of persistent postsurgical pain (PPSP) after breast cancer surgery. 
The introduction of this thesis, Chapter 1, identifies several key questions that needed to 
be addressed in this thesis to further the mechanism-based prediction and prevention of 
PPSP after breast cancer surgery: 1. There is a need to better quantify the magnitude of the 
problem that PPSP after breast cancer surgery constitutes; 2 Demographic and clinical factors 
that are associated with PPSP after breast cancer surgery need to be identified to facilitate 
insight into potential underlying mechanisms and prediction of PPSP; 3. Quantitative sensory 
testing (QST) measurements identifying pathological pain processing changes that may signal 
PPSP development or risk need to be incorporated into studies on PPSP after breast cancer 
by implementing a pragmatic and standardized QST protocol; 4. Preoperative QST measures 
need to be investigated for their potential to predict PPSP after breast cancer surgery; 5. Based 
on PPSP pathophysiology, cyclooxygenase-2 (COX-2) inhibitors need to be investigated as a 
pharmacological PPSP preventative strategy in a clinical trial; and 6. Advances in data science 
outside the pain research specific literature need to be explored for their implementation in 
predicting PPSP after breast cancer surgery. 
In Chapter 2, we presented a study on the prevalence of PPSP after breast cancer surgery. We 
identified that approximately 36% of patients suffered from varying degrees of PPSP six months 
after breast cancer surgery. Additionally, our study was the first to report a relationship in a 
multivariable adjusted model between higher BMI and PPSP following breast cancer treatment. 
We found an increased risk of PPSP of around 4% per 1 kg/m2 increase in BMI. We hypothesized 
that the relationship of BMI with PPSP may be mediated by low-grade inflammation and sensitized 
central pain processing through the release of pro-inflammatory and insulin resistance-inducing 
substances from visceral adipose tissue. The consideration that inflammation plays a role in pain 
sensitization mechanisms and PPSP after breast cancer surgery was further investigated in a 
prospective randomized controlled study in Chapter 5.
To assess the state of science concerning the relationship of QST and PPSP after breast cancer 
surgery and other types of surgery we performed a systematic literature review in Chapter 3. 
Previous systematic reviews had found that patients who preoperatively perceive more pain 
on QST (hyperalgesia), or have impaired endogenous analgesia, experience more acute 
postoperative pain. Higher acute postoperative pain has been shown to be a risk factor for the 
development of PPSP. Because of the strong relationship between preoperative QST measures 
and acute postoperative pain, we hypothesized that preoperative QST measures are strongly 
associated with PPSP. We identified only one study that assessed the relationship between 
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QST measures and PPSP after breast cancer surgery. In that study, no relationship was found 
between preoperative QST measures and PPSP. We also reviewed the literature systematically 
for reported relationships between preoperative QST measures and PPSP in any other types 
of surgery. We found that preoperative conditioned pain modulation, temporal summation of 
pain, and pressure pain threshold were most frequently significantly associated with PPSP with 
variable strengths of association. QST methods were found to vary widely between research 
groups, which limits the generalizability of conclusions to the specific QST methods used and 
their associations. Standardization of protocols across international research groups would 
assist in effective investigation of the association between QST measures and PPSP after breast 
cancer surgery or other types of surgery.
 
To facilitate the standardized assessment of pain thresholds in clinical patients undergoing 
breast cancer surgery we detailed a relatively short standardized QST protocol in Chapter 4. 
Previous standardized QST protocols, such as the German Research Network on Neuropathic 
Pain protocol, are quite extensive and may not be suitable for long-term follow-up with repetitive 
measurements in patients undergoing breast cancer surgery in the context of a clinical trial. 
In Chapter 4 we presented a short protocol to obtain pain thresholds and a measure of 
endogenous analgesia in patients with breast cancer.  The protocol has been published with 
an accompanying instructional video to maximize its dissemination and reproducibility by other 
research groups. 
In Chapter 5 we presented a randomized controlled trial assessing the effect of peri-operative 
COX-2 inhibition on sensitization of pain processing and PPSP after breast cancer surgery. 
This study investigated the potential risk factor of inflammation identified in Chapter 2, while 
applying best practices related to QST in the context of surgical research that were identified 
and demonstrated in Chapters 3 & 4. 138 women undergoing breast cancer surgery under 
general anesthesia with paravertebral block were randomized to receive perioperative COX-
2 inhibition or placebo. We assessed which women developed PPSP up to 12 months after 
surgery. Preoperatively, early postoperatively, and up to 12 months postoperatively, we also 
determined electric and pressure pain tolerance thresholds. We found no differences in pain 
tolerance thresholds or in PPSP between the COX-2 inhibition and placebo groups, indicating 
that COX-2 inhibition has limited value in preventing sensitization and PPSP after breast cancer 
surgery. Consistent with observational studies on PPSP after breast cancer surgery, we found 
that women who developed PPSP demonstrated sensitized processing of pain, as evidenced by 
generalized lower pressure pain tolerance thresholds when compared to women not developing 




In Chapter 6 we discussed a proposed approach to prediction of PPSP after breast cancer 
surgery based on the lessons learned from the RCT presented in Chapter 5, while also 
incorporating our findings regarding QST prediction and clinical risk factors as presented in 
Chapters 2 & 3. We identified a need to develop new prediction strategies using advances 
in data science to facilitate more accurate prediction of PPSP after breast cancer surgery. 
Applying such methods may also accelerate research on the underlying mechanisms of PPSP 
development.
  
In Chapter 7 we discussed the main findings as included in this thesis. Recommendations for 
clinical practice, education, future research, and their societal impact were identified. It is our hope 
that these recommendations will ultimately contribute to improvements in the understanding and 







In dit proefschrift wordt verslag gedaan van onderzoek dat gericht was op het 
voorspellen en voorkómen van chronische pijn na borstkankerchirurgie. De onderzochte 
methoden om chronische pijn te voorspellen of te voorkomen waren zo veel mogelijk 
gebaseerd op de onderliggende veronderstelde pathofysiologie van chronische pijn na 
borstkankerchrurgie. 
In de introductie van dit proefschrift (Hoofdstuk 1) werden de verschillende kernvragen 
gepresenteerd die we wilden beantwoorden door middel van onderzoek om tot betere 
voorspelling en preventie van chronische pijn na borstkankerchirurgie te komen: 1. 
Wat is de incidentie van chronische pijn na borstkankerchirurgie? 2. Welke klinische en 
demografische variabelen gaan gepaard met chronische pijn na borstkankerchirurgie? 3. Zijn 
preoperatieve Quantitative Sensory Testing (QST) metingen in staat om chronische pijn na 
chirurgie te voorspellen? 4. Hoe kunnen QST metingen praktisch geimplementeerd worden 
in onderzoek naar chronische pijn na borstkankerchirurgie? 5. Kunnen cyclooxygenase-2 
(COX-2) remmers pijnsensitisatie en chronische pijn na borstkankerchirurgie voorkomen? 6. 
Hoe kunnen recente ontwikkelingen binnen andere onderzoeksterreinen in data verwerking 
en analyse  gebruikt worden in onderzoek naar chronisch pijn na borstkankerchirurgie? 
In Hoofdstuk 2 wordt een studie gepresenteerd naar de incidentie van chronische 
pijn na borstkankerchirurgie. In het onderzoek vonden we dat 36% van de vrouwen die 
borstkankerchrirugie ondergaan chronische pijn hebben 6 maanden na de ingreep. We 
vonden een relatie tussen een hogere BMI vóór de operatie en chronische pijn 6 maanden na 
de operatie. Voor ieder punt toename in BMI was er een 4% grotere kans om chronische pijn 
te ontwikkelen. We presenteerden een hypothese dat deze relatie mogelijk gebaseerd is op 
inflammatie en sensitisatie samenhanghend met pro-inflammatoire cytokinen uit vetweefsel. 
Deze hypothese werd verder onderzocht in een gerandomiseerde studie in Hoofdstuk 5. 
In Hoofdstuk 3 wordt een systematische literatuurstudie gepresenteerd naar de relatie tussen 
preoperatieve QST metingen en chronische pijn na borstkankerchirurgie en andere typen 
chirurgie. Eerdere systematische literatuurstudies beschreven dat QST metingen vóór een 
operatie sterk gerelateerd zijn aan acute postoperatieve pijn. Van heftige acute postoperatieve 
pijn is bekend dat het een risicofactor is voor chronische pijn na chirurgie. Vanwege de relatie 
tussen preoperatieve QST metingen en acute postoperatieve pijn, en de relatie tussen acute 
postoperatieve pijn en chronische pijn na chirurgie onderzochten we de directe relatie 
tussen preoperatieve QST metingen en chronische pijn na chirurgie. In de literatuurstudie 
vonden we maar 1 studie waarin de relatie tussen tussen preoperatieve QST en chronische 
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pijn na borstkankerchirurgie werd onderzocht. In die studie werd geen verband gevonden 
tussen de testresultaten en chronische pijn na chirurgie. 
In studies naar andere chirurgische ingrepen vertoonden preoperatieve testen van 
geconditioneerde pijnmodulatie, summatie van pijn en testen van drukpijn het vaakst een 
associatie met chronische pijn na chirurgie. De sterkte van de relatie tussen testresultaten 
en chronische pijn was variabel. De methoden die verschillende onderzoeksgroepen 
gebruikten om QST te verrichten om chronische pijn te voorspellen waren erg verschillend. 
De resultaten van de verschillende methoden waren daardoor moeilijk te generaliseren. Het 
standaardiseren van methoden voor QST zou onderzoek naar het voorspellen van pijn na 
borskankerchirurgie (en andere chirurgie) bevorderen. 
In Hoofdstuk 4 van dit proefschift beschreven wij een relatief kort gestandaardiseeerd 
protocol om QST te gebruiken in studies naar chronische pijn na borstkankerchirurgie. 
Andere gestandaardiseerde QST testprotocollen zijn vaak relatief lang en ongeschikt 
om te implementeren in een klinische gerandomiseerde studie naar chronische pijn na 
borstkankerchirurgue. De publicatie van deze methode bevat ook een gedetailleerde 
instructievideo om gebruik van het protocol door andere onderzoeksgroepen te faciliteren.
In Hoofdstuk 5 beschreven we een gerandomiseerde studie naar het effect van 
peri-operatief COX-2 remmers gebruik op postoperatieve sensitisatie en chronische 
pijn na borstkankerchirurgie. In dit onderzoek werd  inflammatie onderzocht als een 
risicofactor (geidentificeerd in Hoofdstuk 2) en werd er gebruik gemaakt van QST 
methoden die onderzocht en ontwikkeld werden in Hoofdstukken 3&4. 138 vrouwen die 
borstkankerchirurgie ondergingen onder algehele anesthesie met paravertebrale blokkade 
als regionale anesthesie werden gerandomiseerd en kregen óf een COX-2 remmer óf 
een placebo rondom en kort na de operatie. Voor de operatie, kort na de operatie en op 
verschillende tijdpunten in het jaar na de operatie maten we pijngevoeligheid door middel 
van QST. We onderzochten welke patienten 12 maanden na chirurgie chronische pijn 
hadden. In het onderzoek vonden we geen verschillen in pijngevoeligheid tussen patienten 
die COX-2 remmers kregen en en patiënten die een placebo kregen rondom hun operatie. 
De patienten die chronische pijn ontwikkelden 12 maanden na hun borstkankeroperatie 
vertoonden kort na de operatie reeds tekenen van pijnsensitisatie in de metingen naar 
pijngevoeligheid door drukstimulatie. 
In Hoofdstuk 6 wordt een nieuwe benadering bediscussieerd en voorgesteld om pijn 
na chirurgie te voorspellen welke gebaseerd is op de resultaten die we verkregen in 
Hoofdstukken 2-5. In de gepresenteerde aanpak is een belangrijke rol weggelegd voor 




gebruikt worden.  Het toepassen van dergelijke technieken heeft mogelijk ook waarde in het 
identificeren van pathofysiologische processen die chronische pijn na borstkankerchirurgie 
veroorzaken. 
In Hoofdstuk 7 worden de belangrijkste resultaten uit het onderzoek besproken en wordt 
gepoogd om antwoorden te formuleren op de in Hoofdstuk 1 gepresenteerde kernvragen. 
Tevens worden aanbevelingen voor de klinische praktijk en wetenschappelijk onderzoek gedaan 







Human clinical research data that were used in this thesis were collected in accordance with 
the principles of the Declaration of Helsinki.1 The medical and ethical review board Committees 
on Research Involving Human Subjects Regions Arnhem Nijmegen and Zuidwest Holland, the 
Netherlands, approved and oversaw these studies.
Data from each study will be saved for 15 years after termination of the respective studies. 
The deidentified datasets relating to the study presented in chapter five are available in the 
KNAW Data Archiving and Networked Services repository (Noud van Helmond [Radboudumc] 
[2016]: Relative Contributions of Humoral and Nerve Nociceptive Inputs to Postoperative 
Central Sensitisation and Pain: Interaction of Extended Perioperative COX-2 Inhibition and Local 
Anaesthetic Blockade for Breast Malignancy Surgery. DANS. https://doi.org/10.17026/dans-xd7-
g3z5) after access approval from the corresponding author upon reasonable request. Approval 
can be requested on the data repository website. 
Signed informed consent forms and case report forms from the study presented in chapter five 
are stored in the archive of Bernhoven Hospital at the Poort van Uden. Case report forms are 
identified by subject numbers to protect against breach of confidentiality. A linking file, containing 
names, dates of birth, and subject numbers is stored independently. Data accuracy against 
source documents can be provided by contacting Gertie Filippini MD (g.filippini@bernhoven.nl) 
or Karin Hermsen MD (k.hermsen@bernhoven.nl). 
Signed informed consent forms and case report forms from the study presented in chapter two 
are stored in the anesthesiology departmental archive at the Reinier de Graaf Hospital in Delft, 
the Netherlands. Case report forms are identified by subject numbers to protect against breach 
of confidentiality. A linking file, containing names, dates of birth, and subject numbers is stored 
independently. Data accuracy against source documents can be provided by contacting Nick 
van Dasselaar MD at N.vanDasselaar@rdgg.nl. Researchers can contact Noud van Helmond 
MD at vanhelmond-noud@cooperhealth.edu to gain access to a deidentified complete data set. 
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